<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer - van Dalen, EC - 2014 | Cochrane Library</title> <meta content="Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer - van Dalen, EC - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006647.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer - van Dalen, EC - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006647.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006647.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer" name="citation_title"/> <meta content="Elvira C van Dalen" name="citation_author"/> <meta content="Emma Children's Hospital/Academic Medical Center" name="citation_author_institution"/> <meta content="e.c.vandalen@amc.uva.nl" name="citation_author_email"/> <meta content="Martine F Raphaël" name="citation_author"/> <meta content="Wilhelmina Children's Hospital, University Medical Center Utrecht" name="citation_author_institution"/> <meta content="Huib N Caron" name="citation_author"/> <meta content="Emma Children's Hospital/Academic Medical Center" name="citation_author_institution"/> <meta content="Leontien CM Kremer" name="citation_author"/> <meta content="Emma Children's Hospital/Academic Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD006647.pub4" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/09/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006647.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006647.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006647.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anthracyclines [adverse effects, *therapeutic use]; Antibiotics, Antineoplastic [adverse effects, *therapeutic use]; Bone Neoplasms [drug therapy]; Heart Diseases [chemically induced]; Hepatoblastoma [drug therapy]; Kidney Neoplasms [drug therapy]; Leukemia, Myeloid, Acute [drug therapy]; Liver Neoplasms [drug therapy]; Lymphoma, Non‐Hodgkin [drug therapy]; Neoplasms [*drug therapy]; Precursor Cell Lymphoblastic Leukemia‐Lymphoma [drug therapy]; Randomized Controlled Trials as Topic; Sarcoma [drug therapy]; Wilms Tumor [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006647.pub4&amp;doi=10.1002/14651858.CD006647.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="0TJL4CWK";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006647\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006647\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006647\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006647\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006647.pub4",title:"Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer",firstPublishedDate:"Sep 4, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Childhood Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=0TJL4CWK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006647.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006647.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006647.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006647.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006647.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006647.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006647.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006647.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006647.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006647.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1856 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006647.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/full#CD006647-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/full#CD006647-sec-0071"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/full#CD006647-sec-0015"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/full#CD006647-sec-0016"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/full#CD006647-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/full#CD006647-sec-0031"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/full#CD006647-sec-0070"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/appendices#CD006647-sec-0086"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/table_n/CD006647StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/table_n/CD006647StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/information#CD006647-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Elvira C van Dalen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/information#CD006647-cr-0003">Martine F Raphaël</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/information#CD006647-cr-0004">Huib N Caron</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006647.pub4/information#CD006647-cr-0005">Leontien CM Kremer</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/information/en#CD006647-sec-0093">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 September 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006647.pub4">https://doi.org/10.1002/14651858.CD006647.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006647-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006647-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006647-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006647-abs-0005">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006647-abs-0001" lang="en"> <section id="CD006647-sec-0001"> <h3 class="title" id="CD006647-sec-0001">Background</h3> <p>One of the most important adverse effects of anthracyclines is cardiotoxicity. A well‐informed decision on the use of anthracyclines in the treatment of childhood cancers should be based on evidence regarding both antitumour efficacy and cardiotoxicity. This review is the second update of a previously published Cochrane review. </p> </section> <section id="CD006647-sec-0002"> <h3 class="title" id="CD006647-sec-0002">Objectives</h3> <p>To compare antitumour efficacy (survival and tumour response) and cardiotoxicity of treatment including or not including anthracyclines in children with childhood cancer. </p> </section> <section id="CD006647-sec-0003"> <h3 class="title" id="CD006647-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i> 2013, Issue 6), MEDLINE (1966 to July 2013) and EMBASE (1980 to July 2013). In addition, we searched reference lists of relevant articles and conference proceedings, the International Society for Paediatric Oncology (SIOP) (from 2002 to 2012) and American Society of Clinical Oncology (ASCO) (from 2002 to 2013). We have searched for ongoing trials in the ISRCTN register and the National Institute of Health register (both screened August 2013) (<a href="http://www.controlled-trials.com/" target="_blank">http://www.controlled‐trials.com</a>). </p> </section> <section id="CD006647-sec-0004"> <h3 class="title" id="CD006647-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) comparing treatment of any type of childhood cancer with and without anthracyclines and reporting outcomes concerning antitumour efficacy or cardiotoxicity. </p> </section> <section id="CD006647-sec-0005"> <h3 class="title" id="CD006647-sec-0005">Data collection and analysis</h3> <p>Two review authors independently performed the study selection, risk of bias assessment and data extraction. Analyses were performed according to the guidelines of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. </p> </section> <section id="CD006647-sec-0006"> <h3 class="title" id="CD006647-sec-0006">Main results</h3> <p>We identified RCTs for seven types of tumour, acute lymphoblastic leukaemia (ALL) (three trials; 912 children), Wilms' tumour (one trial; 316 children), rhabdomyosarcoma and undifferentiated sarcoma (one trial; 413 children), Ewing's sarcoma (one trial; 94 children), non‐Hodgkin lymphoma (one trial; 284 children), hepatoblastoma (one trial; 255 children) and acute myeloid leukaemia (AML) (one trial; 394 children). All studies had methodological limitations. For ALL no evidence of a significant difference in antitumour efficacy was identified in the meta‐analyses, but in most individual studies there was a suggestion of better antitumour efficacy in patients treated with anthracyclines. For both Wilms' tumour and Ewing's sarcoma a significant difference in event‐free and overall survival in favour of treatment with anthracyclines was identified, although for Wilms' tumour the significant difference in overall survival disappeared with long‐term follow‐up. For rhabdomyosarcoma and undifferentiated sarcoma, non‐Hodgkin lymphoma and hepatoblastoma no difference in antitumour efficacy between the treatment groups was identified. The same was true for AML, with the exception of overall survival in a post hoc analysis in a subgroup of patients with relapsed core binding factor (CBF)‐AML in which patients treated with anthracyclines did better. Clinical cardiotoxicity was evaluated in four RCTs; no significant difference between the treatment groups was identified, but in all individual studies there was a suggestion of a lower rate of clinical cardiotoxicity in patients who did not receive anthracyclines. None of the studies evaluated asymptomatic cardiac dysfunction. No RCTs were identified for other childhood cancers. </p> </section> <section id="CD006647-sec-0007"> <h3 class="title" id="CD006647-sec-0007">Authors' conclusions</h3> <p>At the moment no evidence from RCTs is available which underscores the use of anthracyclines in ALL. However, 'no evidence of effect', as identified in this review, is not the same as 'evidence of no effect'. For Wilms' tumour, rhabdomyosarcoma and undifferentiated sarcoma, Ewing's sarcoma, non‐Hodgkin lymphoma, hepatoblastoma and AML only one RCT was available for each type and, therefore, no definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in these tumours. For other childhood cancers no RCTs were identified and therefore no conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in these tumours. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006647-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006647-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006647-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006647-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006647-abs-0003" lang="en"> <h3>Treatment with or without anthracycline chemotherapy for childhood cancer</h3> <p>Anthracyclines are used in the treatment of different types of childhood cancer. Unfortunately, one of the most important adverse effects of anthracyclines is damage to the heart. This can become manifest not only during treatment but also years after the end of treatment. A well‐informed decision on the use of anthracyclines in the treatment of different types of childhood cancer should be based on the available evidence on both the antitumour effects of anthracyclines and the risk of damage to the heart. </p> <p>This systematic review focused on randomised studies evaluating the antitumour effects of anthracycline therapy. The authors found that at the moment no high quality evidence is available which shows that the use of anthracyclines has an increased antitumour effect in acute lymphoblastic leukaemia (ALL) as compared to treatment without anthracyclines, but there was some suggestion that this might be the case. Further high quality studies are needed to provide a definitive conclusion. For Wilms' tumour, rhabdomyosarcoma and undifferentiated sarcoma, Ewing's sarcoma, non‐Hodgkin lymphoma, hepatoblastoma and acute myeloid leukaemia (AML) the review authors found only limited data and were unable to draw conclusions. Also, there were no data for other childhood cancers. More high quality research is needed. At the moment there are five ongoing or unpublished randomised studies evaluating the use of anthracyclines in the following types of childhood cancer, hepatoblastoma, ALL (two studies), rhabdomyosarcoma, and Wilms' tumour. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006647-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006647-sec-0071"></div> <h3 class="title" id="CD006647-sec-0072">Implications for practice</h3> <section id="CD006647-sec-0072"> <p>Anthracycline‐induced cardiotoxicity is a serious and widely prevalent problem in children treated for childhood cancer. Therefore, if anthracycline therapy does not have an added value with regard to antitumour efficacy and adverse effects compared to treatment without anthracyclines, it should not be used in treatment protocols for childhood cancer. </p> <section id="CD006647-sec-0073"> <h5 class="title">ALL</h5> <p>At the moment no evidence from RCTs is available which underscores the use of anthracyclines in ALL. However, it should be noted that 'no evidence of effect', as identified in this review, is not the same as 'evidence of no effect'; the fact that no significant difference in favour of treatment with anthracyclines was identified in this review can be the result of low power, a too short follow‐up period, or the use of low cumulative anthracycline doses. Based on the currently available evidence, we are not able to favour treatment with or without anthracyclines in patients with ALL. </p> </section> <section id="CD006647-sec-0074"> <h5 class="title">Wilms' tumour</h5> <p>Since only one RCT was identified, no definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in patients with a Wilms' tumour. A significant difference in survival in favour of the use of anthracyclines was identified in this study (especially for patients with stage II and III disease) but this finding should be confirmed in other RCTs. Also, it should be kept in mind that with long‐term follow‐up the result of the analysis of all available patients changed from a significant difference in overall survival in favour of treatment with anthracyclines into no significant difference between the treatment groups. </p> </section> <section id="CD006647-sec-0075"> <h5 class="title">Rhabdomyosarcoma<i>and</i> undifferentiated sarcoma </h5> <p>Since only one RCT was identified, no definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in patients with a rhabdomyosarcoma and undifferentiated sarcoma. No difference in antitumour efficacy between treatment with and treatment without anthracyclines was identified, but this finding should be confirmed in other RCTs. </p> </section> <section id="CD006647-sec-0076"> <h5 class="title">Ewing's sarcoma</h5> <p>Since only one RCT was identified, no definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in patients with Ewing's sarcoma. A significant difference in survival in favour of the use of anthracyclines was identified in this study, but this finding should be confirmed in other RCTs. </p> </section> <section id="CD006647-sec-0077"> <h5 class="title">Non‐Hodgkin lymphoma</h5> <p>Since only one RCT was identified, no definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in patients with a non‐Hodgkin lymphoma. No difference in antitumour efficacy was identified between treatment with and without anthracyclines, but this finding should be confirmed in other RCTs. </p> </section> <section id="CD006647-sec-0078"> <h5 class="title">Hepatoblastoma</h5> <p>Since only one RCT was identified, no definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in patients with a hepatoblastoma. No difference in antitumour efficacy between treatment with and without anthracyclines was identified, but this finding should be confirmed in other RCTs. </p> </section> <section id="CD006647-sec-0079"> <h5 class="title">AML</h5> <p>Since only one RCT was identified, no definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in patients with AML. No difference in antitumour efficacy between treatment with and treatment without anthracyclines was identified (with the exception of overall survival in a post hoc analysis in a subgroup of patients with relapsed CBF‐AML in which patients treated with anthracyclines had a better survival) but this finding should be confirmed in other RCTs. </p> </section> <section id="CD006647-sec-0080"> <h5 class="title">Other childhood cancers</h5> <p>For other childhood cancers no RCTs were identified and, therefore, no conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in patients diagnosed with these malignancies. </p> </section> </section> <h3 class="title" id="CD006647-sec-0081">Implications for research</h3> <section id="CD006647-sec-0081"> <section id="CD006647-sec-0082"> <h5 class="title">ALL, Wilms' tumour, rhabdomyosarcoma and undifferentiated sarcoma, Ewing's sarcoma, non‐Hodgkin lymphoma, hepatoblastoma, and AML </h5> <p>Future trials on the use of anthracyclines in patients with these types of tumour should be performed in homogeneous study populations with a long‐term follow‐up using valid outcome definitions (including antitumour efficacy and cardiotoxicity). Different risk groups, different cumulative anthracycline doses, and the age of the patients should be taken into account. It might be feasible to start these RCTs in children with unfavourable prognostic factors. The number of included patients should be sufficient to obtain the power needed for the results to be reliable. We are awaiting the results of the ongoing studies and the studies presented as abstracts during a conference, for patients with ALL, Wilms' tumour, hepatoblastoma and rhabdomyosarcoma. Also, it will be very interesting to examine long‐term survival data from the already performed RCTs. The performance of an individual patient data (IPD) analysis is another possibility to assess the antitumour efficacy of treatment with and without anthracyclines for these childhood cancers. </p> </section> <section id="CD006647-sec-0083"> <h5 class="title">Other childhood cancers</h5> <p>No RCTs were identified for other childhood cancers. Therefore, before definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in patients diagnosed with other malignancies, high quality RCTs need to be undertaken. Again, it might be feasible to start these RCTs in children with unfavourable prognostic factors. Also, these RCTs should be performed in homogeneous study populations with a long‐term follow‐up using valid outcome definitions (including antitumour efficacy and cardiotoxicity). Different risk groups, different cumulative anthracycline doses, and the age of the patients should be taken into account. The number of included patients should be sufficient to obtain the power needed for the results to be reliable. The performance of an IPD analysis is another possibility to assess the antitumour efficacy of treatment with and without anthracyclines for these childhood cancers. </p> </section> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006647-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006647-sec-0015"></div> <p>Anthracyclines, like doxorubicin, daunorubicin and epirubicin, have gained widespread use in the treatment of numerous childhood cancers, both solid tumours and haematological malignancies. Nearly 60% of children diagnosed with a malignancy receive anthracyclines as part of their treatment. </p> <p>Unfortunately, one of the most important side effects of anthracyclines is cardiotoxicity (that is damage to the heart), which has been known since their introduction (<a href="./references#CD006647-bbs2-0217" title="LefrakEA , PithaJ , RosenheimS , GottliebJA . A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer1973;32:302‐14. ">Lefrak 1973</a>). The damage can become manifest in patients as either clinical heart failure (<a href="./references#CD006647-bbs2-0225" title="VonHoffDD , LayardMW , BasaP , DavisHLJr , VonHoffAL , RozencweigM , et al. Risk factors for doxorubicin‐induced congestive heart failure. Annals of Internal Medicine1979;91:710‐7. ">Von Hoff 1979</a>) or asymptomatic cardiac dysfunction (<a href="./references#CD006647-bbs2-0218" title="LipshultzSE , LipsitzSR , SallanSE , DaltonVM , MoneSM , GelberRD , et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. Journal of Clinical Oncology2005;23:2629‐36. ">Lipshultz 2005</a>). Asymptomatic cardiac dysfunction includes various cardiac abnormalities diagnosed with different diagnostic methods, like echocardiography, nuclear angiography, cardiac biopsy or cardiac markers, in asymptomatic patients. Anthracycline‐induced cardiotoxicity is a widely prevalent problem in children; the incidence of clinical heart failure has been reported to be as high as 16% 0.9 to 4.8 years after treatment (<a href="./references#CD006647-bbs2-0212" title="KremerLCM , vanDalenEC , OffringaM , VoutePA . Frequency and risk factors of anthracycline‐induced clinical heart failure in children: a systematic review. Annals of Oncology2002;13:503‐12. ">Kremer 2002a</a>) and the prevalence of asymptomatic cardiac dysfunction has been reported to be more than 57% at a median of 6.4 years after treatment (<a href="./references#CD006647-bbs2-0213" title="KremerLCM , van derPalHJH , OffringaM , vanDalenEC , VoutePA . Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Annals of Oncology2002;13:819‐29. ">Kremer 2002b</a>). The risk of anthracycline‐induced cardiotoxicity is dose‐dependent. In a cohort study of 830 children a cumulative anthracycline dose of 300 mg/m² or more produced an eight‐fold higher risk of clinical heart failure as compared to lower doses (less than 300 mg/m²) (<a href="./references#CD006647-bbs2-0224" title="VanDalenEC , van derPalHJ , KokWE , CaronHN , KremerLCM . Clinical heart failure in a cohort of children treated with anthracyclines: a long‐term follow‐up study. European Journal of Cancer2006;42:3191‐8. ">Van Dalen 2006</a>). The consequences of anthracycline‐induced cardiotoxicity are extensive. It can lead to long‐term side effects, causing severe morbidity and reduced quality of life. The cardiotoxicity involves long‐term treatment and thus high medical costs and it causes premature death. The excess mortality due to cardiac disease is eight‐fold higher than expected for long‐term survivors of childhood cancer compared to the normal population (<a href="./references#CD006647-bbs2-0219" title="MertensAC , YasuiY , NegliaJP , PotterJD , NesbitMEJr , RuccioneK , et al. Late mortality experience in five‐year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. Journal of Clinical Oncology2001;19:3163‐72. ">Mertens 2001</a>). </p> <p>If anthracycline therapy does not have an added value with regard to tumour response and survival compared to treatment without anthracyclines, it should not be used in treatment protocols for childhood cancer. As a result, anthracycline‐induced cardiotoxicity would not be an issue. Although ample evidence supports the antileukaemic activity of anthracyclines administered as a single drug, data supporting anthracycline use in modern multi‐drug combinations, which now constitute the mainstay of current acute lymphoblastic leukaemia (ALL) treatments, are lacking. It is unclear if the use of anthracyclines improves the outcome (<a href="./references#CD006647-bbs2-0220" title="MessingerY , UckunFM . A critical risk‐benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia. Leukemia &amp; Lymphoma1999;34:415‐32. ">Messinger 1999</a>). Also, in a randomised controlled trial (RCT) in children with advanced stage non‐lymphoblastic non‐Hodgkin's lymphoma, the addition of daunorubicin to treatment with COMP (intrathecal arabinofuranosyl cytidine (ARA‐C), cyclophosphamide, vincristine, methotrexate and prednisone) did not improve the prognosis; children treated with daunorubicin had an event‐free survival of 57%, whereas in children treated without daunorubicin the event‐free survival was 55% (no significant difference) (<a href="./references#CD006647-bbs2-0013" title="SpostoR , MeadowsAT , ChilcoteRR , SteinherzPG , KjeldsbergC , KadinME , et al. Comparison of long‐term outcome of children and adolescents with disseminated non‐lymphoblastic non‐Hodgkin lymphoma treated with COMP or daunomycin‐COMP: A report from the Children's Cancer Group. Medical and Pediatric Oncology2001;37:432‐41. ">Sposto 2001</a>). </p> <p>This is the second update of the first systematic review evaluating the state of the evidence on the use of anthracyclines in the treatment of childhood cancer. </p> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006647-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006647-sec-0016"></div> <p><b>Primary objective:</b> </p> <p> <ul id="CD006647-list-0001"> <li> <p>to compare survival in children with any type of malignancy receiving anthracyclines as part of their treatment with survival in children not receiving anthracyclines as part of their treatment. </p> </li> </ul> </p> <p><b>Secondary objectives:</b> </p> <p> <ul id="CD006647-list-0002"> <li> <p>to compare tumour response in both treatment groups;</p> </li> <li> <p>to compare cardiotoxicity in both treatment groups.</p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006647-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006647-sec-0017"></div> <section id="CD006647-sec-0018"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006647-sec-0019"> <h4 class="title">Types of studies</h4> <p>RCTs comparing treatment of childhood cancer with and without anthracyclines.</p> </section> <section id="CD006647-sec-0020"> <h4 class="title">Types of participants</h4> <p>Children (aged 0 to 18 years at diagnosis) with any type of malignancy at any stage. RCTs including both children and adults were only eligible for inclusion in this review if the majority of participants were children and the maximal age of the participants did not exceed 30 years. </p> </section> <section id="CD006647-sec-0021"> <h4 class="title">Types of interventions</h4> <p>Treatment with and without anthracyclines. Therapy other than anthracyclines (that is chemotherapy, cardioprotective interventions, radiotherapy or surgery, or a combination) should have been the same in both treatment groups. Timing of different aspects of the treatment may have differed between the study groups, but the cumulative doses of therapy other than anthracyclines should not have differed more than 25% between the study groups. Furthermore, prior treatment should have been comparable in both treatment groups. </p> </section> <section id="CD006647-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD006647-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006647-list-0003"> <li> <p>Survival (overall survival and event‐free survival as defined by the authors of the original study) </p> </li> </ul> </p> </section> <section id="CD006647-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006647-list-0004"> <li> <p>Tumour response (as defined by the authors of the original study)</p> </li> <li> <p>Anthracycline‐induced cardiotoxicity (i.e. clinical heart failure (as defined by the authors of the original study) or asymptomatic cardiac dysfunction (defined as either histological abnormalities according to the Billingham score (<a href="./references#CD006647-bbs2-0204" title="BillinghamME , MasonJW , BristowMR , DanielsJR . Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treatment Reports1978;62:865‐72. ">Billingham 1978</a>) on myocardial biopsies or abnormalities in cardiac function measured by echocardiography or radionuclide ventriculography)) </p> </li> </ul> </p> </section> </section> </section> <section id="CD006647-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <p>The following electronic databases have been searched:<br/> The Cochrane Central Library of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i> 2013, Issue 6), MEDLINE in PubMed (from 1966 to July 2013), and EMBASE in Ovid (from 1980 to July 2013). The search strategies for the different electronic databases (using a combination of controlled vocabulary and text word terms) are detailed in the appendices (<a href="./appendices#CD006647-sec-0087">Appendix 1</a>, <a href="./appendices#CD006647-sec-0088">Appendix 2</a>, <a href="./appendices#CD006647-sec-0089">Appendix 3</a>). </p> <p>Information about trials not registered in CENTRAL, MEDLINE or EMBASE, either published or unpublished, was located by searching the reference lists of relevant articles and review articles. We also scanned the conference proceedings of the International Society for Paediatric Oncology (SIOP) (from 2002 to 2012) and American Society of Clinical Oncology (ASCO) (from 2002 to 2013), if available electronically and otherwise by handsearching. We have searched for ongoing trials in the ISRCTN register and the National Institute of Health register (both screened August 2013) (<a href="http://www.controlled-trials.com/" target="_blank">http://www.controlled‐trials.com</a>). Language restrictions were not imposed. </p> </section> <section id="CD006647-sec-0026"> <h3 class="title" id="CD006647-sec-0026">Data collection and analysis</h3> <section id="CD006647-sec-0027"> <h4 class="title">Selection of studies</h4> <p>For the original version of the review, after employing the search strategy described previously, initial screening of identified references was performed by one review author. Case reports, studies only including adults, studies in which all patients received anthracyclines, and review articles were excluded. Identification of studies meeting the inclusion criteria from the remaining references was undertaken by two review authors working independently. Any study which seemed to meet the inclusion criteria on the grounds of the title or abstract, or both, was obtained in full for closer inspection. Again, for the original version of the review, initial screening was performed by one review author who excluded case reports, studies only including adults, studies in which all patients received anthracyclines, and review articles. The remaining full text articles were evaluated by two independent review authors. For both updates of the review, two independent review authors performed all steps of the study identification process (that is no initial screening by one review author). Details of the reasons for exclusion of any study considered for the review were clearly stated. Discrepancies between review authors were resolved by consensus or if that was not possible by third party arbitration. </p> </section> <section id="CD006647-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently performed the data extraction using standardised forms. Data on the following items were extracted: </p> <p>(1) Study design.</p> <p>(2) Risk of bias items.</p> <p>(3) Participants, including:<br/> a. age;<br/> b. sex;<br/> c. type of tumour;<br/> d. stage of disease;<br/> e. primary tumour or recurrence;<br/> f. prior treatment;<br/> g. number of patients entering the trial;<br/> h. number of patients randomised;<br/> i. number of patients excluded (with reasons);<br/> j. number of patients evaluable (for each outcome). </p> <p>(4) Interventions, including:<br/> a. type of anthracycline;<br/> b. cumulative anthracycline dose;<br/> c. anthracycline peak dose (defined as the maximal dose received in one week);<br/> d. anthracycline infusion duration;<br/> e. other treatment, including:<br/> i. chemotherapy (agent and cumulative dose),<br/> ii. radiotherapy (location and cumulative dose),<br/> iii. surgery (location and procedure),<br/> iv. cardioprotective interventions (method). </p> <p>(5) Outcome measures.</p> <p>(6) Length of follow‐up.</p> <p>Discrepancies between review authors were resolved by consensus. No third party arbitration was needed. </p> </section> <section id="CD006647-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias in the included RCTs. For this second update we used the most recent recommendations of the Childhood Cancer Group (that is selection bias, performance bias, detection bias (for each outcome separately), attrition bias (for each outcome separately), reporting bias (where 'all expected outcomes' was defined as reporting on both overall survival and cardiotoxicity and at least one of the following outcomes: event‐free survival or tumour response) and other bias). We used the 'risk of bias' items and definitions of low risk, unclear risk and high risk as described in the module of the Cochrane Childhood Cancer Group (<a href="./references#CD006647-bbs2-0214" title="KremerLCM , vanDalenEC , MoherD , CaronHN . Cochrane Childhood Cancer Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2008, issue 3. ">Kremer 2008</a>), which is based on the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006647-bbs2-0211" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). All RCTs (including those already included in earlier versions of the review) were scored using the new 'risk of bias' items. Discrepancies between authors were resolved by discussion. No third party arbitration was needed. The risk of bias in the included studies was taken into account in the interpretation of the review's results. </p> </section> <section id="CD006647-sec-0030"> <h4 class="title">Data synthesis</h4> <p>Data were entered into RevMan and analysed according to the guidelines of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006647-bbs2-0210" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane‐handbook.org. ">Higgins 2009</a>). Dichotomous variables were related to risk using the relative risk or risk ratio (RR). If possible, data were extracted by allocation intervention, irrespective of compliance with the allocated intervention, in order to allow an 'intention‐to‐treat' (ITT) analysis. If this was not possible, this was stated and we performed an 'as treated' analysis. We assessed heterogeneity both by visual inspection of the forest plots and by a formal statistical test for heterogeneity, that is the I² statistic. If there was evidence of substantial heterogeneity (I² &gt; 50%) (<a href="./references#CD006647-bbs2-0210" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane‐handbook.org. ">Higgins 2009</a>) this was reported. Studies for which pooling of results was not possible were summarised descriptively. We used a random‐effects model for the estimation of treatment effects throughout the review. All results were presented with the corresponding 95% confidence interval (CI). For the assessment of survival, we used the generic inverse variance function of RevMan to combine logs of the hazard ratios (HRs). We used Parmar's method if HRs had not been explicitly presented in the study (<a href="./references#CD006647-bbs2-0221" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815‐34. ">Parmar 1998</a>). Data were analysed separately for different types of tumour and, if possible, also for different stages of disease and different histological subtypes. When a particular outcome was not evaluated in more than 50% of the patients of a study, due to the associated high risk of attrition bias we did not report the results of this outcome measure. For all outcomes for which pooled analyses were possible we performed sensitivity analyses for all risk of bias criteria separately. We excluded studies with a high risk of bias and studies for which the risk of bias was unclear and compared the results of the studies with a low risk of bias with the results of all available studies. The risk of bias in the studies included in the analyses was taken into account in the interpretation of the results of the review. We were not able to construct a funnel plot to graphically ascertain the existence of publication bias. As a rule of thumb, tests for funnel plot asymmetry should be used only when there are at least 10 studies included in a meta‐analysis. When there are fewer studies the power of the test is too low to distinguish chance from real asymmetry (<a href="./references#CD006647-bbs2-0210" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane‐handbook.org. ">Higgins 2009</a>). Since only a maximum of three trials could be included in the separate meta‐analyses, we did not construct funnel plots. For outcomes where only one study was available, we were unable to calculate a RR if one of the treatment groups experienced no events and the Fischer’s exact test was used instead; this option is not available in Revman and therefore we used http://graphpad.com/quickcalcs/contingency2/. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006647-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006647-sec-0031"></div> <section id="CD006647-sec-0032"> <h3 class="title">Description of studies</h3> <p>Running the searches in the electronic databases of CENTRAL, MEDLINE in PubMed and EMBASE in Ovid (in January 2007) yielded a total of 3277 references. Initial screening excluded 987 references based on them being case reports, review articles, studies only including adults, or studies in which all patients received anthracyclines. Of the 2290 remaining references 135 studies were assessed in full. Of the 67 articles remaining after initial screening, we included a total of seven articles which fulfilled all the criteria for this review. A total of 128 articles were excluded after assessing the full text articles, for reasons described in the <a href="./references#CD006647-sec-0100" title="">Characteristics of excluded studies</a> table. The remaining 2155 references were excluded based on the title or abstract, or both, since they were not a RCT, were laboratory studies, were animal studies, did not include children with cancer, or there was a difference in treatment other than anthracyclines between the treatment groups. </p> <p>Running the searches for the update in CENTRAL, MEDLINE in PubMed and EMBASE in Ovid (in March 2010) yielded a total of 1032 new references. Following screening of the titles, abstracts, or both, 1000 references which clearly did not meet all criteria for considering studies for this review were excluded. We obtained 32 articles in full, of which a single article fulfilled all the criteria for considering studies for this review (<a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>). The other 31 articles were excluded for reasons described in the <a href="./references#CD006647-sec-0100" title="">Characteristics of excluded studies</a> table. </p> <p>Running the searches for the second update in CENTRAL, MEDLINE in PubMed and EMBASE in Ovid (in July 2013) yielded a total of 1167 new references. Following screening of the titles, abstracts, or both, 1151 references which clearly did not meet all criteria for considering studies for this review were excluded. We obtained 16 articles in full (five of these were only available as a conference proceeding), of which a single article fulfilled all the criteria for considering studies for this review (<a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>). Thirteen articles were excluded for reasons described in the <a href="./references#CD006647-sec-0100" title="">Characteristics of excluded studies</a> table; two studies have not been published in full yet (see <a href="./references#CD006647-sec-0101" title="">Characteristics of studies awaiting classification</a> table). </p> <p>Scanning the reference lists of relevant articles and reviews did not identify any additional eligible studies. We did identify three ongoing trials during the original review. At the time of the first update one ongoing trial identified in the original version of this review was published in full text and identified in the update of the electronic database searches (<a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>); this trial was thus removed from the <a href="./references#CD006647-sec-0102" title="">Characteristics of ongoing studies</a> table. At the time of the second update it became clear that the SIOP‐2001 trial was closed and preliminary results had been presented as a conference proceeding (identified in the second update of the electronic database searches as described above); this trial was thus removed from the <a href="./references#CD006647-sec-0102" title="">Characteristics of ongoing studies</a> table. Eleven other studies (nine from the original version and two from the first update) were added to the <a href="./references#CD006647-sec-0100" title="">Characteristics of excluded studies</a> table. </p> <p>By scanning the conference proceedings of SIOP and ASCO for the original version, we identified one study (described in two abstracts) that had not been published in full yet and was awaiting further assessment during the original search. At the time of the updates this study is still not published in full (see the <a href="./references#CD006647-sec-0101" title="">Characteristics of studies awaiting classification</a> table); no other additional eligible studies were identified during the updates. </p> <p>By scanning the ongoing trials databases for the original version we identified three additional ongoing trials (see the <a href="./references#CD006647-sec-0102" title="">Characteristics of ongoing studies</a> table); no other additional eligible studies were identified during the updates but it became clear that the ISRCTN94206677 and the NCT00186966 trials were in fact the same study and that the study was published in full text and identified in the second update of the electronic database searches (<a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>); these publications were thus removed from the <a href="./references#CD006647-sec-0102" title="">Characteristics of ongoing studies</a> table. </p> <p>Finally, during the first update an expert in the field provided us with long‐term follow‐up data (<a href="./references#CD006647-bbs2-0208" title="GreenDM . The treatment of stages I‐IV favorable histology Wilms' tumor. Journal of Clinical Oncology2004;22:1366‐72. ">Green 2004</a>) of one of the included studies (<a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a>). </p> <p>In summary, after the second update the total number of included RCTs was nine. We also identified two ongoing studies and three studies that have not been published in full yet and are awaiting further assessment. </p> <p>Characteristics of the included studies are summarised below; for more information we refer to the <a href="./references#CD006647-sec-0099" title="">Characteristics of included studies</a> table. </p> <p>The total number of patients included in the nine identified RCTs was 2668: 1318 children received no anthracyclines, whereas 1350 did receive anthracyclines. In three studies children were diagnosed with ALL (<a href="./references#CD006647-bbs2-0006" title="EdenOB , LilleymanJS , RichardsS , ShawMP , PetoJ . Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology1991;78:187‐96. ">Eden 1991</a>; <a href="./references#CD006647-bbs2-0014" title="Van derDoes‐van den BergA , deKoningJ , ReerinkH , deVriesJA , vanZanenGE . Acute lymphatic leukemia in children in the Netherlands; study ALL I, 1972‐1973; Dutch Childhood Leukemia Study Group [Acute lymfatische leukemie bij kinderen in Nederland; onderzoek ALL I, 1972‐1973; Stichting Nederlandse Werkgroep Leukemie bij Kinderen (SNWLK)]. Nederlands Tijdschrift voor Geneeskunde1975;119:1445‐51. ">Van der Does 1975</a>; <a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a>); and in one with acute myeloid leukemia (AML) (<a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>). In the other five studies they were diagnosed with a solid tumour: Wilms' tumour (<a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a>), rhabdomyosarcoma or undifferentiated sarcoma (<a href="./references#CD006647-bbs2-0008" title="MaurerHM , BeltangadyM , GehanEA , CristW , HammondD , HaysDM , et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer1988;61:209‐20. ">Maurer 1988</a>), Ewing's sarcoma (<a href="./references#CD006647-bbs2-0011" title="NesbitMEJr , GehanEA , BurgertEOJr , ViettiTJ , CangirA , TefftM , et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long‐term follow‐up of the First Intergroup study. Journal of Clinical Oncology1990;8:1664‐74. ">Nesbit 1990</a>), non‐Hodgkin lymphoma (<a href="./references#CD006647-bbs2-0013" title="SpostoR , MeadowsAT , ChilcoteRR , SteinherzPG , KjeldsbergC , KadinME , et al. Comparison of long‐term outcome of children and adolescents with disseminated non‐lymphoblastic non‐Hodgkin lymphoma treated with COMP or daunomycin‐COMP: A report from the Children's Cancer Group. Medical and Pediatric Oncology2001;37:432‐41. ">Sposto 2001</a>) or hepatoblastoma (<a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>). In four studies patients were treated with daunorubicin (<a href="./references#CD006647-bbs2-0006" title="EdenOB , LilleymanJS , RichardsS , ShawMP , PetoJ . Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology1991;78:187‐96. ">Eden 1991</a>; <a href="./references#CD006647-bbs2-0013" title="SpostoR , MeadowsAT , ChilcoteRR , SteinherzPG , KjeldsbergC , KadinME , et al. Comparison of long‐term outcome of children and adolescents with disseminated non‐lymphoblastic non‐Hodgkin lymphoma treated with COMP or daunomycin‐COMP: A report from the Children's Cancer Group. Medical and Pediatric Oncology2001;37:432‐41. ">Sposto 2001</a>; <a href="./references#CD006647-bbs2-0014" title="Van derDoes‐van den BergA , deKoningJ , ReerinkH , deVriesJA , vanZanenGE . Acute lymphatic leukemia in children in the Netherlands; study ALL I, 1972‐1973; Dutch Childhood Leukemia Study Group [Acute lymfatische leukemie bij kinderen in Nederland; onderzoek ALL I, 1972‐1973; Stichting Nederlandse Werkgroep Leukemie bij Kinderen (SNWLK)]. Nederlands Tijdschrift voor Geneeskunde1975;119:1445‐51. ">Van der Does 1975</a>; <a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a>). In all these studies the cumulative daunorubicin dose actually received by the patients was not mentioned, but according to protocol patients should have received 90 to 350 mg/m². The peak anthracycline dose (that is the maximal dose received in one week) ranged from 25 to 90 mg/m². Infusion durations were not mentioned. In four studies patients were treated with doxorubicin (<a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a>; <a href="./references#CD006647-bbs2-0008" title="MaurerHM , BeltangadyM , GehanEA , CristW , HammondD , HaysDM , et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer1988;61:209‐20. ">Maurer 1988</a>; <a href="./references#CD006647-bbs2-0011" title="NesbitMEJr , GehanEA , BurgertEOJr , ViettiTJ , CangirA , TefftM , et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long‐term follow‐up of the First Intergroup study. Journal of Clinical Oncology1990;8:1664‐74. ">Nesbit 1990</a>; <a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>). In all these studies the cumulative doxorubicin dose actually received by the patients was not mentioned, but according to protocol patients should have received either (maximal) 300 or 420 mg/m². The peak anthracycline dose (that is the maximal dose received in one week) was either 25 or 60 mg/m². Infusion durations were not mentioned in three studies, in the other study it was 30 mg/m<sup>2</sup>/24 hours. In the final study patients were treated with daunoxome, that is liposomally entrapped daunorubicin (<a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>). The cumulative daunoxome dose actually received by the patients was not mentioned, but according to protocol patients should have received 180 mg/m<sup>2</sup>. The peak anthracycline dose (that is the maximal dose received in one week) was 180 mg/m<sup>2</sup>. The infusion duration was not mentioned. </p> </section> <section id="CD006647-sec-0033"> <h3 class="title">Risk of bias in included studies</h3> <p>See the risk of bias section of the <a href="./references#CD006647-sec-0099" title="">Characteristics of included studies</a> table and <a href="#CD006647-fig-0001">Figure 1</a> for the exact scores per included study. </p> <div class="figure" id="CD006647-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006647-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD006647-sec-0034"> <h4 class="title">Allocation</h4> <p>For evaluating selection bias we have assessed the random sequence generation and the allocation concealment. The risk of selection bias was low in two studies (22%) (<a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>; <a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>), while in seven studies (78%) it was unclear (<a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a>; <a href="./references#CD006647-bbs2-0006" title="EdenOB , LilleymanJS , RichardsS , ShawMP , PetoJ . Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology1991;78:187‐96. ">Eden 1991</a>; <a href="./references#CD006647-bbs2-0008" title="MaurerHM , BeltangadyM , GehanEA , CristW , HammondD , HaysDM , et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer1988;61:209‐20. ">Maurer 1988</a>; <a href="./references#CD006647-bbs2-0011" title="NesbitMEJr , GehanEA , BurgertEOJr , ViettiTJ , CangirA , TefftM , et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long‐term follow‐up of the First Intergroup study. Journal of Clinical Oncology1990;8:1664‐74. ">Nesbit 1990</a>; <a href="./references#CD006647-bbs2-0013" title="SpostoR , MeadowsAT , ChilcoteRR , SteinherzPG , KjeldsbergC , KadinME , et al. Comparison of long‐term outcome of children and adolescents with disseminated non‐lymphoblastic non‐Hodgkin lymphoma treated with COMP or daunomycin‐COMP: A report from the Children's Cancer Group. Medical and Pediatric Oncology2001;37:432‐41. ">Sposto 2001</a>; <a href="./references#CD006647-bbs2-0014" title="Van derDoes‐van den BergA , deKoningJ , ReerinkH , deVriesJA , vanZanenGE . Acute lymphatic leukemia in children in the Netherlands; study ALL I, 1972‐1973; Dutch Childhood Leukemia Study Group [Acute lymfatische leukemie bij kinderen in Nederland; onderzoek ALL I, 1972‐1973; Stichting Nederlandse Werkgroep Leukemie bij Kinderen (SNWLK)]. Nederlands Tijdschrift voor Geneeskunde1975;119:1445‐51. ">Van der Does 1975</a>; <a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a>). For the latter study only the random sequence generation was unclear and the allocation concealment was adequate; for the other six studies both items were unclear. </p> </section> <section id="CD006647-sec-0035"> <h4 class="title">Blinding</h4> <p>For evaluating performance bias we have assessed the blinding of participants and personnel. In two studies (22%) there was a high risk of bias (<a href="./references#CD006647-bbs2-0006" title="EdenOB , LilleymanJS , RichardsS , ShawMP , PetoJ . Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology1991;78:187‐96. ">Eden 1991</a>; <a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>), while in seven studies (78%) it was unclear (<a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a>; <a href="./references#CD006647-bbs2-0008" title="MaurerHM , BeltangadyM , GehanEA , CristW , HammondD , HaysDM , et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer1988;61:209‐20. ">Maurer 1988</a>; <a href="./references#CD006647-bbs2-0011" title="NesbitMEJr , GehanEA , BurgertEOJr , ViettiTJ , CangirA , TefftM , et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long‐term follow‐up of the First Intergroup study. Journal of Clinical Oncology1990;8:1664‐74. ">Nesbit 1990</a>; <a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>; <a href="./references#CD006647-bbs2-0013" title="SpostoR , MeadowsAT , ChilcoteRR , SteinherzPG , KjeldsbergC , KadinME , et al. Comparison of long‐term outcome of children and adolescents with disseminated non‐lymphoblastic non‐Hodgkin lymphoma treated with COMP or daunomycin‐COMP: A report from the Children's Cancer Group. Medical and Pediatric Oncology2001;37:432‐41. ">Sposto 2001</a>; <a href="./references#CD006647-bbs2-0014" title="Van derDoes‐van den BergA , deKoningJ , ReerinkH , deVriesJA , vanZanenGE . Acute lymphatic leukemia in children in the Netherlands; study ALL I, 1972‐1973; Dutch Childhood Leukemia Study Group [Acute lymfatische leukemie bij kinderen in Nederland; onderzoek ALL I, 1972‐1973; Stichting Nederlandse Werkgroep Leukemie bij Kinderen (SNWLK)]. Nederlands Tijdschrift voor Geneeskunde1975;119:1445‐51. ">Van der Does 1975</a>; <a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a>). </p> <p>For evaluating detection bias we have evaluated the blinding of outcome assessors for all separate outcomes, with the exception of overall survival since for that outcome blinding is not relevant and the risk of detection bias was thus automatically judged as low for all eight studies (100%) evaluating this outcome (<a href="./references#CD006647-bbs2-0006" title="EdenOB , LilleymanJS , RichardsS , ShawMP , PetoJ . Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology1991;78:187‐96. ">Eden 1991</a>; <a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>; <a href="./references#CD006647-bbs2-0008" title="MaurerHM , BeltangadyM , GehanEA , CristW , HammondD , HaysDM , et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer1988;61:209‐20. ">Maurer 1988</a>; <a href="./references#CD006647-bbs2-0011" title="NesbitMEJr , GehanEA , BurgertEOJr , ViettiTJ , CangirA , TefftM , et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long‐term follow‐up of the First Intergroup study. Journal of Clinical Oncology1990;8:1664‐74. ">Nesbit 1990</a>; <a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>; <a href="./references#CD006647-bbs2-0014" title="Van derDoes‐van den BergA , deKoningJ , ReerinkH , deVriesJA , vanZanenGE . Acute lymphatic leukemia in children in the Netherlands; study ALL I, 1972‐1973; Dutch Childhood Leukemia Study Group [Acute lymfatische leukemie bij kinderen in Nederland; onderzoek ALL I, 1972‐1973; Stichting Nederlandse Werkgroep Leukemie bij Kinderen (SNWLK)]. Nederlands Tijdschrift voor Geneeskunde1975;119:1445‐51. ">Van der Does 1975</a>; <a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a>). Six studies evaluated event‐free survival; in all studies (100%) the risk of detection bias was unclear (<a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a>; <a href="./references#CD006647-bbs2-0006" title="EdenOB , LilleymanJS , RichardsS , ShawMP , PetoJ . Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology1991;78:187‐96. ">Eden 1991</a>; <a href="./references#CD006647-bbs2-0011" title="NesbitMEJr , GehanEA , BurgertEOJr , ViettiTJ , CangirA , TefftM , et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long‐term follow‐up of the First Intergroup study. Journal of Clinical Oncology1990;8:1664‐74. ">Nesbit 1990</a>; <a href="./references#CD006647-bbs2-0013" title="SpostoR , MeadowsAT , ChilcoteRR , SteinherzPG , KjeldsbergC , KadinME , et al. Comparison of long‐term outcome of children and adolescents with disseminated non‐lymphoblastic non‐Hodgkin lymphoma treated with COMP or daunomycin‐COMP: A report from the Children's Cancer Group. Medical and Pediatric Oncology2001;37:432‐41. ">Sposto 2001</a>; <a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>; <a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a>). Five studies evaluated tumour response; in four studies (80%) the risk of detection bias was unclear (<a href="./references#CD006647-bbs2-0006" title="EdenOB , LilleymanJS , RichardsS , ShawMP , PetoJ . Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology1991;78:187‐96. ">Eden 1991</a>; <a href="./references#CD006647-bbs2-0008" title="MaurerHM , BeltangadyM , GehanEA , CristW , HammondD , HaysDM , et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer1988;61:209‐20. ">Maurer 1988</a>; <a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>; <a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a>) while in one study (20%) the risk was judged to be high (<a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>). Five studies evaluated cardiotoxicity; in four studies (80%) the risk of detection bias was unclear (<a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a>; <a href="./references#CD006647-bbs2-0008" title="MaurerHM , BeltangadyM , GehanEA , CristW , HammondD , HaysDM , et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer1988;61:209‐20. ">Maurer 1988</a>; <a href="./references#CD006647-bbs2-0011" title="NesbitMEJr , GehanEA , BurgertEOJr , ViettiTJ , CangirA , TefftM , et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long‐term follow‐up of the First Intergroup study. Journal of Clinical Oncology1990;8:1664‐74. ">Nesbit 1990</a>; <a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>) while in one study (20%) the risk was judged to be high (<a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>). </p> </section> <section id="CD006647-sec-0036"> <h4 class="title">Incomplete outcome data</h4> <p>For evaluating attrition bias we have assessed incomplete outcome data for all separate outcomes. Eight studies evaluated overall survival; in five studies (63%) there was a low risk of attrition bias (<a href="./references#CD006647-bbs2-0006" title="EdenOB , LilleymanJS , RichardsS , ShawMP , PetoJ . Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology1991;78:187‐96. ">Eden 1991</a>; <a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>; <a href="./references#CD006647-bbs2-0011" title="NesbitMEJr , GehanEA , BurgertEOJr , ViettiTJ , CangirA , TefftM , et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long‐term follow‐up of the First Intergroup study. Journal of Clinical Oncology1990;8:1664‐74. ">Nesbit 1990</a>; <a href="./references#CD006647-bbs2-0014" title="Van derDoes‐van den BergA , deKoningJ , ReerinkH , deVriesJA , vanZanenGE . Acute lymphatic leukemia in children in the Netherlands; study ALL I, 1972‐1973; Dutch Childhood Leukemia Study Group [Acute lymfatische leukemie bij kinderen in Nederland; onderzoek ALL I, 1972‐1973; Stichting Nederlandse Werkgroep Leukemie bij Kinderen (SNWLK)]. Nederlands Tijdschrift voor Geneeskunde1975;119:1445‐51. ">Van der Does 1975</a>; <a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a>), in one study (12%) there was a high risk of attrition bias (<a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>) and in two studies (25%) the risk of attrition bias was unclear (<a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a>; <a href="./references#CD006647-bbs2-0008" title="MaurerHM , BeltangadyM , GehanEA , CristW , HammondD , HaysDM , et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer1988;61:209‐20. ">Maurer 1988</a>). Six studies evaluated event‐free survival; in three studies (50%) there was a low risk of attrition bias (<a href="./references#CD006647-bbs2-0006" title="EdenOB , LilleymanJS , RichardsS , ShawMP , PetoJ . Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology1991;78:187‐96. ">Eden 1991</a>; <a href="./references#CD006647-bbs2-0011" title="NesbitMEJr , GehanEA , BurgertEOJr , ViettiTJ , CangirA , TefftM , et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long‐term follow‐up of the First Intergroup study. Journal of Clinical Oncology1990;8:1664‐74. ">Nesbit 1990</a>; <a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a>), in one study (17%) there was a high risk of attrition bias (<a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>) and in two studies (33%) the risk of attrition bias was unclear (<a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a>; <a href="./references#CD006647-bbs2-0013" title="SpostoR , MeadowsAT , ChilcoteRR , SteinherzPG , KjeldsbergC , KadinME , et al. Comparison of long‐term outcome of children and adolescents with disseminated non‐lymphoblastic non‐Hodgkin lymphoma treated with COMP or daunomycin‐COMP: A report from the Children's Cancer Group. Medical and Pediatric Oncology2001;37:432‐41. ">Sposto 2001</a>). Five studies evaluated tumour response; in all studies (100%) the risk of attrition bias was low (<a href="./references#CD006647-bbs2-0006" title="EdenOB , LilleymanJS , RichardsS , ShawMP , PetoJ . Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology1991;78:187‐96. ">Eden 1991</a>; <a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>; <a href="./references#CD006647-bbs2-0008" title="MaurerHM , BeltangadyM , GehanEA , CristW , HammondD , HaysDM , et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer1988;61:209‐20. ">Maurer 1988</a>; <a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>; <a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a>). Five studies evaluated cardiotoxicity; in two studies (40%) the risk of attrition bias was high (<a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>; <a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>) while in three studies (60%) it was unclear (<a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a>; <a href="./references#CD006647-bbs2-0008" title="MaurerHM , BeltangadyM , GehanEA , CristW , HammondD , HaysDM , et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer1988;61:209‐20. ">Maurer 1988</a>; <a href="./references#CD006647-bbs2-0011" title="NesbitMEJr , GehanEA , BurgertEOJr , ViettiTJ , CangirA , TefftM , et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long‐term follow‐up of the First Intergroup study. Journal of Clinical Oncology1990;8:1664‐74. ">Nesbit 1990</a>). </p> </section> <section id="CD006647-sec-0037"> <h4 class="title">Selective reporting</h4> <p>For evaluating reporting bias we have assessed selective reporting. We defined 'all expected outcomes' as reporting on both overall survival and cardiotoxicity and at least one of the following outcomes: event‐free survival or tumour response. In five studies (56%) we judged the risk of reporting bias to be low (<a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a>; <a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>; <a href="./references#CD006647-bbs2-0008" title="MaurerHM , BeltangadyM , GehanEA , CristW , HammondD , HaysDM , et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer1988;61:209‐20. ">Maurer 1988</a>; <a href="./references#CD006647-bbs2-0011" title="NesbitMEJr , GehanEA , BurgertEOJr , ViettiTJ , CangirA , TefftM , et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long‐term follow‐up of the First Intergroup study. Journal of Clinical Oncology1990;8:1664‐74. ">Nesbit 1990</a>; <a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>) while in four studies (44%) it was judged to be high (<a href="./references#CD006647-bbs2-0006" title="EdenOB , LilleymanJS , RichardsS , ShawMP , PetoJ . Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology1991;78:187‐96. ">Eden 1991</a>; <a href="./references#CD006647-bbs2-0013" title="SpostoR , MeadowsAT , ChilcoteRR , SteinherzPG , KjeldsbergC , KadinME , et al. Comparison of long‐term outcome of children and adolescents with disseminated non‐lymphoblastic non‐Hodgkin lymphoma treated with COMP or daunomycin‐COMP: A report from the Children's Cancer Group. Medical and Pediatric Oncology2001;37:432‐41. ">Sposto 2001</a>; <a href="./references#CD006647-bbs2-0014" title="Van derDoes‐van den BergA , deKoningJ , ReerinkH , deVriesJA , vanZanenGE . Acute lymphatic leukemia in children in the Netherlands; study ALL I, 1972‐1973; Dutch Childhood Leukemia Study Group [Acute lymfatische leukemie bij kinderen in Nederland; onderzoek ALL I, 1972‐1973; Stichting Nederlandse Werkgroep Leukemie bij Kinderen (SNWLK)]. Nederlands Tijdschrift voor Geneeskunde1975;119:1445‐51. ">Van der Does 1975</a>; <a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a>). </p> </section> <section id="CD006647-sec-0038"> <h4 class="title">Other potential sources of bias</h4> <p>For evaluating other potential sources of bias we have assessed the following items: block randomisation in unblinded trials, baseline imbalance between treatment groups related to outcome (prior cardiotoxic treatment, age, sex, prior cardiac dysfunction), difference in length of follow‐up between treatment arms, and inappropriate influence of funders. In one study (11%) there was a high risk of other bias (<a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>) while in the other eight studies (89%) the risk was unclear (<a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a>; <a href="./references#CD006647-bbs2-0006" title="EdenOB , LilleymanJS , RichardsS , ShawMP , PetoJ . Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology1991;78:187‐96. ">Eden 1991</a>; <a href="./references#CD006647-bbs2-0008" title="MaurerHM , BeltangadyM , GehanEA , CristW , HammondD , HaysDM , et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer1988;61:209‐20. ">Maurer 1988</a>; <a href="./references#CD006647-bbs2-0011" title="NesbitMEJr , GehanEA , BurgertEOJr , ViettiTJ , CangirA , TefftM , et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long‐term follow‐up of the First Intergroup study. Journal of Clinical Oncology1990;8:1664‐74. ">Nesbit 1990</a>; <a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>; <a href="./references#CD006647-bbs2-0013" title="SpostoR , MeadowsAT , ChilcoteRR , SteinherzPG , KjeldsbergC , KadinME , et al. Comparison of long‐term outcome of children and adolescents with disseminated non‐lymphoblastic non‐Hodgkin lymphoma treated with COMP or daunomycin‐COMP: A report from the Children's Cancer Group. Medical and Pediatric Oncology2001;37:432‐41. ">Sposto 2001</a>; <a href="./references#CD006647-bbs2-0014" title="Van derDoes‐van den BergA , deKoningJ , ReerinkH , deVriesJA , vanZanenGE . Acute lymphatic leukemia in children in the Netherlands; study ALL I, 1972‐1973; Dutch Childhood Leukemia Study Group [Acute lymfatische leukemie bij kinderen in Nederland; onderzoek ALL I, 1972‐1973; Stichting Nederlandse Werkgroep Leukemie bij Kinderen (SNWLK)]. Nederlands Tijdschrift voor Geneeskunde1975;119:1445‐51. ">Van der Does 1975</a>; <a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a>). For a more detailed description of all the different items see the risk of bias section of the <a href="http://www.archie.cochrane.org/sections/documents/view?document=60533348873545919391101216111740%26format=REVMAN#CHARACTERISTICS_OF_INCLUDED_STUDIES" target="_blank">Characteristics of included studies</a> table. </p> </section> </section> <section id="CD006647-sec-0039"> <h3 class="title" id="CD006647-sec-0039">Effects of interventions</h3> <p>Not all articles allowed data extraction for all endpoints (see the <a href="./references#CD006647-sec-0099" title="">Characteristics of included studies</a> table for a more detailed description of the extractable endpoints of each article). </p> <section id="CD006647-sec-0040"> <h4 class="title">Overall survival</h4> <p>(See <a href="#CD006647-fig-0002">Figure 2</a>) </p> <div class="figure" id="CD006647-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.1 Overall survival (Parmar's method was used to obtain the necessary data for the meta‐analyses)." data-id="CD006647-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.1 Overall survival (Parmar's method was used to obtain the necessary data for the meta‐analyses). </p> </div> </div> </div> <section id="CD006647-sec-0041"> <h5 class="title">ALL</h5> <p>Data on overall survival could be extracted from three trials with a total of 912 patients (<a href="./references#CD006647-bbs2-0006" title="EdenOB , LilleymanJS , RichardsS , ShawMP , PetoJ . Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology1991;78:187‐96. ">Eden 1991</a>; <a href="./references#CD006647-bbs2-0014" title="Van derDoes‐van den BergA , deKoningJ , ReerinkH , deVriesJA , vanZanenGE . Acute lymphatic leukemia in children in the Netherlands; study ALL I, 1972‐1973; Dutch Childhood Leukemia Study Group [Acute lymfatische leukemie bij kinderen in Nederland; onderzoek ALL I, 1972‐1973; Stichting Nederlandse Werkgroep Leukemie bij Kinderen (SNWLK)]. Nederlands Tijdschrift voor Geneeskunde1975;119:1445‐51. ">Van der Does 1975</a>; <a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a>). Parmar's method was used to obtain the necessary data for the meta‐analysis. The HR showed no significant difference between treatment not including and treatment including anthracyclines (HR 1.22, 95% CI 0.95 to 1.57, P = 0.13). No heterogeneity was detected (I<sup>2</sup> = 0%). </p> </section> <section id="CD006647-sec-0042"> <h5 class="title">Wilms' tumour</h5> <p>Data on overall survival could be extracted from one trial with a total of 316 patients (<a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a>). Data were presented separately for patients with stage II or III disease with favourable histology, stage II or III with unfavourable histology, and stage IV disease. Parmar's method was used to obtain the necessary data for the analysis. The combination of all patients showed a significant difference in favour of treatment including anthracyclines (HR 1.85, 95% CI 1.09 to 3.15, P = 0.02). No heterogeneity was detected (I<sup>2</sup> = 0%). For patients with stage II or III disease with favourable histology and patients with stage IV disease the analyses showed no significant difference between treatment not including and treatment including anthracyclines. However, the analysis of patients with stage II or III with unfavourable histology showed a significant difference in favour of treatment including anthracyclines (HR 3.10, 95% CI 1.03 to 9.28, P = 0.04). </p> <p>Long‐term follow‐up data of this study have been published (<a href="./references#CD006647-bbs2-0208" title="GreenDM . The treatment of stages I‐IV favorable histology Wilms' tumor. Journal of Clinical Oncology2004;22:1366‐72. ">Green 2004</a>; <a href="./references#CD006647-bbs2-0003" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. GreenDM . The treatment of stages I‐IV favorable histology Wilms' tumor. Journal of Clinical Oncology2004;22:1366‐72. ">D'Angio 1981 II‐III FH UH</a>; <a href="./references#CD006647-bbs2-0005" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. GreenDM . The treatment of stages I‐IV favorable histology Wilms' tumor. Journal of Clinical Oncology2004;22:1366‐72. ">D'Angio 1981 IV</a>) on 275 of 316 patients: 227 patients with stage II or III disease with favourable or unfavourable histology (as opposed to <a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a> in which data were presented separately for favourable and unfavourable histology) and 48 patients with stage IV disease. The length of follow‐up was not mentioned but at least some of the patients had a follow‐up of 16 years. See <a href="#CD006647-fig-0003">Figure 3</a> for the long‐term follow‐up data. In contrast to the earlier results, the long‐term follow‐up data showed no significant difference between treatment groups (HR 1.27, 95% CI 0.77 to 2.11, P = 0.34). No heterogeneity was detected (I<sup>2</sup> = 0%). The long‐term follow‐up data also showed no significant difference between treatment groups for patients with stage II or III disease with favourable or unfavourable histology and for patients with stage IV disease. These results are in line with the earlier data; in <a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a> the overall survival of patients with stage II or III disease with favourable or unfavourable histology combined was not significantly different between treatment groups (HR 1.92, 95% CI 0.91 to 4.04, P = 0.09, I<sup>2</sup> = 19%; data not shown in the figures). Please note that it was not possible to perform an ITT analysis: in the stage IV group 20 patients were included in the no anthracycline group and 28 in the anthracycline group, as opposed to the original data where 22 patients were randomised to the anthracycline group and 27 to the non‐anthracycline group. </p> <div class="figure" id="CD006647-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.5 Overall survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the analyses)." data-id="CD006647-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.5 Overall survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the analyses). </p> </div> </div> </div> </section> <section id="CD006647-sec-0043"> <h5 class="title">Rhabdomyosarcoma and undifferentiated sarcoma</h5> <p>Data on overall survival could be extracted from one trial with a total of 413 patients (<a href="./references#CD006647-bbs2-0008" title="MaurerHM , BeltangadyM , GehanEA , CristW , HammondD , HaysDM , et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer1988;61:209‐20. ">Maurer 1988</a>). Data were presented for patients in clinical groups III and IV separately. Parmar's method was used to obtain the necessary data for the analysis. The combination of both clinical groups showed no significant difference between treatment not including and treatment including anthracyclines (HR 1.04, 95% CI 0.83 to 1.29, P = 0.76). The same was true for each clinical group separately. No heterogeneity was detected (I<sup>2</sup> = 0%). </p> </section> <section id="CD006647-sec-0044"> <h5 class="title">Ewing's sarcoma</h5> <p>Overall survival was evaluated in one trial (<a href="./references#CD006647-bbs2-0011" title="NesbitMEJr , GehanEA , BurgertEOJr , ViettiTJ , CangirA , TefftM , et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long‐term follow‐up of the First Intergroup study. Journal of Clinical Oncology1990;8:1664‐74. ">Nesbit 1990</a>). Only some of the patients included in this trial were eligible for inclusion in this review (N = 94) and, unfortunately, not all data needed for a correct analysis of overall survival in only the eligible patients were provided in the article. Therefore, we provided descriptive results of overall survival in only the eligible patients. There was evidence of a significant advantage in overall survival for patients treated with anthracyclines as compared to patients treated without anthracyclines (P = 0.02). </p> </section> <section id="CD006647-sec-0045"> <h5 class="title">Non‐Hodgkin lymphoma</h5> <p>Overall survival could not be evaluated since we were not able to reliably extract the data needed to use Parmar's method for the assessment of this outcome from this study (<a href="./references#CD006647-bbs2-0013" title="SpostoR , MeadowsAT , ChilcoteRR , SteinherzPG , KjeldsbergC , KadinME , et al. Comparison of long‐term outcome of children and adolescents with disseminated non‐lymphoblastic non‐Hodgkin lymphoma treated with COMP or daunomycin‐COMP: A report from the Children's Cancer Group. Medical and Pediatric Oncology2001;37:432‐41. ">Sposto 2001</a>). </p> </section> <section id="CD006647-sec-0046"> <h5 class="title">Hepatoblastoma</h5> <p>Overall survival was evaluated in one trial with a total of 255 patients (<a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>). Parmar's method was used to obtain the necessary data for the analysis. The HR showed no significant difference between treatment not including and treatment including anthracyclines (HR 1.14, 95% CI 0.41 to 3.16, P = 0.80). Please note that it was not possible to perform an ITT analysis: 12 randomised patients were excluded (seven lacked proper documentation, five had wrong diagnosis; it was unclear to which treatment group these patients were randomised). </p> </section> <section id="CD006647-sec-0047"> <h5 class="title">AML</h5> <p>Overall survival was evaluated in one trial with a total of 394 patients (<a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>). Parmar's method was used to obtain the necessary data for the analysis. The HR showed no significant difference between treatment not including and treatment including anthracyclines (HR 1.16, 95% CI 0.94 to 1.44, P = 0.17). </p> </section> </section> <section id="CD006647-sec-0048"> <h4 class="title">Event‐free survival</h4> <p>(See <a href="#CD006647-fig-0004">Figure 4</a>) </p> <div class="figure" id="CD006647-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.2 Event‐free survival (Parmar's method was used to obtain the necessary data for the meta‐analyses)." data-id="CD006647-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.2 Event‐free survival (Parmar's method was used to obtain the necessary data for the meta‐analyses). </p> </div> </div> </div> <section id="CD006647-sec-0049"> <h5 class="title">ALL</h5> <p>Data on event‐free survival could be extracted from two trials with a total of 870 patients (<a href="./references#CD006647-bbs2-0006" title="EdenOB , LilleymanJS , RichardsS , ShawMP , PetoJ . Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology1991;78:187‐96. ">Eden 1991</a>; <a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a>). Parmar's method was used to obtain the necessary data for the meta‐analysis. The HR showed no significant difference between treatment not including and treatment including anthracyclines (HR 1.05, 95% CI 0.76 to 1.46, P = 0.77). However, unexplained heterogeneity was detected (I<sup>2</sup> = 56%). In the study of <a href="./references#CD006647-bbs2-0014" title="Van derDoes‐van den BergA , deKoningJ , ReerinkH , deVriesJA , vanZanenGE . Acute lymphatic leukemia in children in the Netherlands; study ALL I, 1972‐1973; Dutch Childhood Leukemia Study Group [Acute lymfatische leukemie bij kinderen in Nederland; onderzoek ALL I, 1972‐1973; Stichting Nederlandse Werkgroep Leukemie bij Kinderen (SNWLK)]. Nederlands Tijdschrift voor Geneeskunde1975;119:1445‐51. ">Van der Does 1975</a> no information on event‐free survival was provided. </p> </section> <section id="CD006647-sec-0050"> <h5 class="title">Wilms' tumour</h5> <p>Data on event‐free survival could be extracted from one trial with a total of 316 patients (<a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a>). Data were presented separately for patients with stage II or III disease with favourable histology, stage II or III with unfavourable histology, and stage IV disease. Parmar's method was used to obtain the necessary data for the analysis. The combination of all patients showed a significant difference in favour of treatment including anthracyclines (HR 2.21, 95% CI 1.44 to 3.40, P = 0.0003). No heterogeneity was detected (I<sup>2</sup> = 0%). The analysis of patients with stage II or III disease with favourable histology also showed a significant difference in favour of treatment including anthracyclines (HR 2.56, 95% CI 1.42 to 4.61, P = 0.002). However, for patients with stage II or III disease with unfavourable histology and patients with stage IV disease the analyses showed no significant difference between treatment not including and treatment including anthracyclines. </p> <p>Long‐term follow‐up data of this study have been published (<a href="./references#CD006647-bbs2-0208" title="GreenDM . The treatment of stages I‐IV favorable histology Wilms' tumor. Journal of Clinical Oncology2004;22:1366‐72. ">Green 2004</a>; <a href="./references#CD006647-bbs2-0003" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. GreenDM . The treatment of stages I‐IV favorable histology Wilms' tumor. Journal of Clinical Oncology2004;22:1366‐72. ">D'Angio 1981 II‐III FH UH</a>; <a href="./references#CD006647-bbs2-0005" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. GreenDM . The treatment of stages I‐IV favorable histology Wilms' tumor. Journal of Clinical Oncology2004;22:1366‐72. ">D'Angio 1981 IV</a>) on 275 of 316 patients: 227 patients with stage II or III disease with favourable or unfavourable histology (as opposed to <a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a>, data were not presented separately for favourable and unfavourable histology) and 48 patients with stage IV disease. The length of follow‐up was not mentioned but at least some of the patients had a follow‐up of 16 years. See <a href="#CD006647-fig-0005">Figure 5</a> for the long‐term follow‐up data, which also showed a significant difference in favour of treatment including anthracyclines (HR 1.72, 95% CI 1.09 to 2.72, P = 0.02). No heterogeneity was detected (I<sup>2</sup> = 0%). For the different stages or histologies the results of the long‐term follow‐up data were also in line with the earlier data, that is a significant difference in favour of treatment including anthracyclines for patients with stage II or III disease with favourable or unfavourable histology (for the long‐term follow‐up: HR 1.80, 95% CI 1.04 to 3.12, P = 0.04; for the earlier follow‐up: HR 2.21, 95% CI 1.35 to 3.62, P = 0.002, I<sup>2</sup> = 0%; data not shown in the figures); and no significant difference between treatment groups for patients with stage IV disease. Please note that it was not possible to perform an ITT analysis: in the stage IV group 20 patients were included in the no anthracycline group and 28 in the anthracycline group, as opposed to the original data where 22 patients were randomised to the anthracycline group and 27 to the non‐anthracycline group. </p> <div class="figure" id="CD006647-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.6 Event‐free survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the analyses)." data-id="CD006647-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.6 Event‐free survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the analyses). </p> </div> </div> </div> </section> <section id="CD006647-sec-0051"> <h5 class="title">Rhabdomyosarcoma and undifferentiated sarcoma</h5> <p>Event‐free survival could not be evaluated since we were not able to reliably extract the data needed to use Parmar's method for the assessment of this outcome from this study (<a href="./references#CD006647-bbs2-0008" title="MaurerHM , BeltangadyM , GehanEA , CristW , HammondD , HaysDM , et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer1988;61:209‐20. ">Maurer 1988</a>). </p> </section> <section id="CD006647-sec-0052"> <h5 class="title">Ewing's sarcoma</h5> <p>Event‐free survival was evaluated in one trial (<a href="./references#CD006647-bbs2-0011" title="NesbitMEJr , GehanEA , BurgertEOJr , ViettiTJ , CangirA , TefftM , et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long‐term follow‐up of the First Intergroup study. Journal of Clinical Oncology1990;8:1664‐74. ">Nesbit 1990</a>). Only some of the patients included in this trial were eligible for inclusion in this review and, unfortunately, not all data needed for a correct analysis of event‐free survival in only these patients were provided in the article. Therefore, we provide descriptive results of event‐free survival in only the eligible patients. There was evidence of a significant advantage in event‐free survival for patients treated with anthracyclines as compared to patients treated without anthracyclines (P = 0.01). </p> </section> <section id="CD006647-sec-0053"> <h5 class="title">Non‐Hodgkin lymphoma</h5> <p>Data on event‐free survival could be extracted from one trial with a total of 284 patients (<a href="./references#CD006647-bbs2-0013" title="SpostoR , MeadowsAT , ChilcoteRR , SteinherzPG , KjeldsbergC , KadinME , et al. Comparison of long‐term outcome of children and adolescents with disseminated non‐lymphoblastic non‐Hodgkin lymphoma treated with COMP or daunomycin‐COMP: A report from the Children's Cancer Group. Medical and Pediatric Oncology2001;37:432‐41. ">Sposto 2001</a>). Parmar's method was used to obtain the necessary data for the analysis. The HR showed no significant difference between treatment not including and treatment including anthracyclines (HR 1.01, 95% CI 0.74 to 1.38, P = 0.95). </p> </section> <section id="CD006647-sec-0054"> <h5 class="title">Hepatoblastoma</h5> <p>Event‐free survival was evaluated in one trial with a total of 255 patients (<a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>). Parmar's method was used to obtain the necessary data for the analysis. The data showed no significant difference between treatment not including and treatment including anthracyclines (HR 0.81, 95% CI 0.42 to 1.55, P = 0.52). Please note that it was not possible to perform an ITT analysis: 12 randomised patients were excluded (seven lacked proper documentation, five had wrong diagnosis; it was unclear to which treatment group these patients were randomised). </p> </section> <section id="CD006647-sec-0055"> <h5 class="title">AML</h5> <p>No information on event‐free survival was provided (<a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>). </p> </section> </section> <section id="CD006647-sec-0056"> <h4 class="title">Tumour response</h4> <p>(See <a href="#CD006647-fig-0006">Figure 6</a>) </p> <div class="figure" id="CD006647-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.3 Tumour response." data-id="CD006647-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.3 Tumour response. </p> </div> </div> </div> <p>Please note that due to the nature of this outcome (that is the number of patients with a remission) a high event rate is favourable. Therefore, in the figures of the analyses, 'favours anthracyclines' is on the left and 'favours no anthracyclines' is on the right, as opposed to the figures of the other analyses. </p> <section id="CD006647-sec-0057"> <h5 class="title">ALL</h5> <p>Data on tumour response (defined as the number of patients in complete remission) could be extracted from two studies with a total of 870 patients (<a href="./references#CD006647-bbs2-0006" title="EdenOB , LilleymanJS , RichardsS , ShawMP , PetoJ . Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology1991;78:187‐96. ">Eden 1991</a>; <a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a>). The meta‐analysis showed no significant difference between treatment not including and treatment including anthracyclines (RR 1.02, 95% CI 0.99 to 1.06, P = 0.22). No substantial heterogeneity was detected (I<sup>2</sup> = 15%).<br/> We excluded the study of <a href="./references#CD006647-bbs2-0014" title="Van derDoes‐van den BergA , deKoningJ , ReerinkH , deVriesJA , vanZanenGE . Acute lymphatic leukemia in children in the Netherlands; study ALL I, 1972‐1973; Dutch Childhood Leukemia Study Group [Acute lymfatische leukemie bij kinderen in Nederland; onderzoek ALL I, 1972‐1973; Stichting Nederlandse Werkgroep Leukemie bij Kinderen (SNWLK)]. Nederlands Tijdschrift voor Geneeskunde1975;119:1445‐51. ">Van der Does 1975</a> from this analysis since no data on tumour response was provided separately in either treatment group. </p> </section> <section id="CD006647-sec-0058"> <h5 class="title">Wilms' tumour</h5> <p>No information on tumour response was provided (<a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a>). </p> </section> <section id="CD006647-sec-0059"> <h5 class="title">Rhabdomyosarcoma and undifferentiated sarcoma</h5> <p>Data on tumour response (defined as the number of patients in complete or partial remission) could be extracted from one trial with a total of 413 patients (<a href="./references#CD006647-bbs2-0008" title="MaurerHM , BeltangadyM , GehanEA , CristW , HammondD , HaysDM , et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer1988;61:209‐20. ">Maurer 1988</a>). The analysis showed no significant difference between treatment not including and treatment including anthracyclines (RR 1.00, 95% CI 0.91 to 1.09, P = 0.95). </p> </section> <section id="CD006647-sec-0060"> <h5 class="title">Ewing's sarcoma</h5> <p>No information on tumour response was provided (<a href="./references#CD006647-bbs2-0011" title="NesbitMEJr , GehanEA , BurgertEOJr , ViettiTJ , CangirA , TefftM , et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long‐term follow‐up of the First Intergroup study. Journal of Clinical Oncology1990;8:1664‐74. ">Nesbit 1990</a>). </p> </section> <section id="CD006647-sec-0061"> <h5 class="title">Non‐Hodgkin lymphoma</h5> <p>No information on tumour response was provided (<a href="./references#CD006647-bbs2-0013" title="SpostoR , MeadowsAT , ChilcoteRR , SteinherzPG , KjeldsbergC , KadinME , et al. Comparison of long‐term outcome of children and adolescents with disseminated non‐lymphoblastic non‐Hodgkin lymphoma treated with COMP or daunomycin‐COMP: A report from the Children's Cancer Group. Medical and Pediatric Oncology2001;37:432‐41. ">Sposto 2001</a>). </p> </section> <section id="CD006647-sec-0062"> <h5 class="title">Hepatoblastoma</h5> <p>Tumour response (defined as complete surgical resection, that is resection of all tumour sites on the basis of surgical findings and on postsurgical imaging) was evaluated in one trial with a total of 255 patients (<a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>). The analysis showed no significant difference between treatment not including and treatment including anthracyclines (RR 1.02, 95% CI 0.96 to 1.08, P = 0.61). Please note that it was not possible to perform an ITT analysis: 12 randomised patients were excluded (seven lacked proper documentation, five had wrong diagnosis; it was unclear to which treatment group these patients were randomised). </p> </section> <section id="CD006647-sec-0063"> <h5 class="title">AML</h5> <p>Tumour response (that is complete response after two courses defined as 5% or fewer leukaemic blasts in bone marrow with signs of normal haematopoiesis and of regeneration of normal peripheral blood cell production (platelets &gt; 50 x 10<sup>9</sup>/L without transfusions, neutrophils &gt; 1.0 x 10<sup>9</sup>/L) and no leukaemic cells in the peripheral blood or anywhere else) was evaluated in one trial with a total of 394 patients (<a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>). The analysis showed no significant difference between treatment not including and treatment including anthracyclines (RR 0.87, 95% CI 0.75 to 1.01, P = 0.06). </p> </section> </section> <section id="CD006647-sec-0064"> <h4 class="title">Cardiotoxicity</h4> <p>(See <a href="#CD006647-fig-0007">Figure 7</a>) </p> <div class="figure" id="CD006647-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.4 Clinical cardiotoxicity." data-id="CD006647-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.4 Clinical cardiotoxicity. </p> </div> </div> </div> <section id="CD006647-sec-0065"> <h5 class="title">Cardiac death</h5> <p>Data on cardiac death could be extracted from two trials with a total of 410 patients with Wilms' tumour or Ewing's sarcoma (<a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a>; <a href="./references#CD006647-bbs2-0011" title="NesbitMEJr , GehanEA , BurgertEOJr , ViettiTJ , CangirA , TefftM , et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long‐term follow‐up of the First Intergroup study. Journal of Clinical Oncology1990;8:1664‐74. ">Nesbit 1990</a>). The meta‐analysis showed no significant difference between treatment not including and treatment including anthracyclines (RR 0.41, 95% CI 0.04 to 3.89, P = 0.44). No heterogeneity was detected (I<sup>2</sup> = 0%). </p> </section> <section id="CD006647-sec-0066"> <h5 class="title">Congestive heart failure</h5> <p>Data on congestive heart failure could be extracted from one trial with a total of 413 patients with rhabdomyosarcoma and undifferentiated sarcoma (<a href="./references#CD006647-bbs2-0008" title="MaurerHM , BeltangadyM , GehanEA , CristW , HammondD , HaysDM , et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer1988;61:209‐20. ">Maurer 1988</a>). Since in one of the treatment groups there were no events (0 out of 208 children in the group without anthracyclines experienced congestive heart failure as opposed to 1 out of 205 children in the group with anthracyclines) we were unable to calculate a RR, so we used the Fischer’s exact test instead. The analysis showed no significant difference between treatment not including and treatment including anthracyclines (Fischer's exact P = 0.50). </p> </section> <section id="CD006647-sec-0067"> <h5 class="title">Asymptomatic cardiac dysfunction</h5> <p>We could collect data on asymptomatic cardiac dysfunction from one trial with a total of 255 patients with hepatoblastoma (<a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a>). However, due to the high risk of attrition bias (this outcome was evaluated in only 49% of the patients), results of this study were not reported. </p> </section> <section id="CD006647-sec-0068"> <h5 class="title">Grade 3 or 4 acute cardiotoxicity according to National Cancer Institute Common Toxicity Criteria (NCI CTC) version 2 </h5> <p>Data on grade 3 or 4 acute cardiotoxicity according to the NCI CTC Criteria version 2 could be extracted from one trial with a total of 394 patients with AML (<a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>). The analysis showed no significant difference between treatment not including and treatment including anthracyclines (RR 0.20, 95% CI 0.02 to 1.70, P = 0.14). </p> <p>In the studies of <a href="./references#CD006647-bbs2-0006" title="EdenOB , LilleymanJS , RichardsS , ShawMP , PetoJ . Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology1991;78:187‐96. ">Eden 1991</a>; <a href="./references#CD006647-bbs2-0013" title="SpostoR , MeadowsAT , ChilcoteRR , SteinherzPG , KjeldsbergC , KadinME , et al. Comparison of long‐term outcome of children and adolescents with disseminated non‐lymphoblastic non‐Hodgkin lymphoma treated with COMP or daunomycin‐COMP: A report from the Children's Cancer Group. Medical and Pediatric Oncology2001;37:432‐41. ">Sposto 2001</a>; <a href="./references#CD006647-bbs2-0014" title="Van derDoes‐van den BergA , deKoningJ , ReerinkH , deVriesJA , vanZanenGE . Acute lymphatic leukemia in children in the Netherlands; study ALL I, 1972‐1973; Dutch Childhood Leukemia Study Group [Acute lymfatische leukemie bij kinderen in Nederland; onderzoek ALL I, 1972‐1973; Stichting Nederlandse Werkgroep Leukemie bij Kinderen (SNWLK)]. Nederlands Tijdschrift voor Geneeskunde1975;119:1445‐51. ">Van der Does 1975</a> and <a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a> no (reliable) information on cardiotoxicity was provided. </p> </section> </section> <section id="CD006647-sec-0069"> <h4 class="title">Sensitivity analyses for the used quality criteria</h4> <p>The results of the sensitivity analyses were consistent among the trials and did not differ from the overall analyses. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006647-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006647-sec-0070"></div> <p>Anthracycline‐induced cardiotoxicity is a considerable and serious problem, causing severe morbidity and mortality. With the current improved cancer survival rates, the problem of late‐onset cardiotoxicity is increasing. The risk of developing heart failure remains a lifelong threat, especially to children who have a long life‐expectancy after successful antineoplastic treatment. If anthracycline therapy does not have an added value with regard to tumour response and survival compared to treatment without anthracyclines, it should not be used in treatment protocols for childhood cancer. As a result anthracycline‐induced cardiotoxicity would not be an issue. This is the second update of the first systematic review evaluating the current state of evidence on the use of anthracyclines in the treatment of childhood cancer. Only RCTs were included since it is widely recognized that a RCT is the only study design which can be used to obtain unbiased evidence on the use of anthracyclines, provided that the design and execution are adequate. </p> <p>We could identify RCTs for seven types of tumour, ALL, Wilms' tumour, rhabdomyosarcoma and undifferentiated sarcoma, Ewing's sarcoma, non‐Hodgkin lymphoma, hepatoblastoma, and AML. Either the use of doxorubicin or (liposomally entrapped) daunorubicin was evaluated. </p> <p>For ALL three trials were identified, all evaluating the use of daunorubicin. Our meta‐analysis of these three trials showed no evidence of a significant difference in overall survival between the treatment groups. Our meta‐analysis of two trials also showed no evidence of a significant difference in event‐free survival between the treatment groups (unexplained heterogeneity was detected). However, a long‐term cardiac follow‐up study of one of these studies (<a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a>) mentioned that the five‐year and 10‐year event‐free survival of patients treated with anthracyclines were significantly better than for patients treated without anthracyclines (P = 0.047 and P = 0.038, respectively) (<a href="./references#CD006647-bbs2-0148" title="RammelooLA , PostmaA , Sobotka‐PlojharMA , Bink‐BoelkensMT , BergA , VeermanAJ , et al. Low‐dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long‐term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group. Medical and Pediatric Oncology2000;35:13‐9. ">Rammeloo 2000</a>). Our meta‐analysis of two trials showed no evidence of a significant difference in tumour response (defined as the number of patients in complete remission) between the treatment groups. Please note that the reason that no significant difference between the treatment groups was identified could be due to the fact that the numbers of patients included in these studies were too small to detect a difference between the treatment groups (that is low power). Also, the length of follow‐up could be too short to detect a significant difference between the treatment groups. In most individual studies there is some suggestion of better survival in patients treated with anthracyclines. It should be noted that all these RCTs are performed in a different treatment era and not all RCTs stated the risk group(s) of included children. Nowadays most children with ALL are cured (<a href="./references#CD006647-bbs2-0222" title="PietersR , CarrollWL . Biology and treatment of acute lymphoblastic leukemia. Pediatric Clinics of North America2008;55:1‐20. ">Pieters 2008</a>), while in the studies included in this review approximately 70% of the children survived. </p> <p>For Wilms' tumour one trial was identified, evaluating the use of doxorubicin. Our analysis of all patients included in this trial showed a significant difference in overall survival in favour of treatment including anthracyclines as compared to treatment without anthracyclines (HR 1.85, 95% CI 1.09 to 3.15, P = 0.02). However, when patients with different stages of disease and different tumour histologies were analysed separately, this result was confirmed only in patients with stage II or III disease with unfavourable histology (HR 3.10, 95% CI 1.03 to 9.28, P = 0.04). For patients with stage II or III disease with favourable histology and patients with stage IV disease there was no evidence of a significant difference in overall survival between the treatment groups. However, with long‐term follow‐up (that is the exact length of follow‐up was unclear, but at least some of the patients had a follow‐up of 16 years), the overall result changed from a significant difference in favour of treatment with anthracyclines into no significant difference between the treatment groups. A possible explanation could be the mortality caused by different late effects (<a href="./references#CD006647-bbs2-0219" title="MertensAC , YasuiY , NegliaJP , PotterJD , NesbitMEJr , RuccioneK , et al. Late mortality experience in five‐year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. Journal of Clinical Oncology2001;19:3163‐72. ">Mertens 2001</a>; <a href="./references#CD006647-bbs2-0223" title="ReulenRC , WinterDL , FrobisherC , LancashireER , StillerCA , JenneyME , et al. Long‐term cause‐specific mortality among survivors of childhood cancer. JAMA2010;304:172‐9. ">Reulen 2010</a>). Our analysis of all patients included in this trial showed a significant difference in event‐free survival in favour of treatment including anthracyclines as compared to treatment without anthracyclines (HR 2.21, 95% CI 1.44 to 3.40, P = 0.0003). However, when patients with different stages of disease and different tumour histologies were analysed separately, this result was confirmed only in patients with stage II or III disease with favourable histology (HR 2.56, 95% CI 1.42 to 4.61, P = 0.002). For patients with stage II or III disease with unfavourable histology and patients with stage IV disease there was no evidence of a significant difference in event‐free survival between the treatment groups. The results of event‐free survival did not change with long‐term follow‐up (HR 1.72, 95% CI 1.09 to 2.72, P = 0.02). No information on tumour response was provided and, therefore, no conclusions can be made regarding this outcome. Please note that the reason that a significant difference between the treatment groups was not found for all stages of disease and tumour histologies could be due to the fact that the numbers of patients included in these studies were too small to detect a difference between the treatment groups (that is low power). The direction of the results of the different stages of disease and different tumour histologies were the same as the overall result. </p> <p>For rhabdomyosarcoma and undifferentiated sarcoma one trial was identified, evaluating the use of doxorubicin. Our analysis of all patients included in this trial showed no evidence of a significant difference in overall survival between the treatment groups. When patients in different clinical groups (that is clinical groups III and IV) were analysed separately, again no evidence of a significant difference between the treatment groups was identified. It was not possible to evaluate event‐free survival in this study and, therefore, no conclusions can be made regarding this outcome. Our analysis showed no significant difference in tumour response (defined as the number of patients in complete or partial remission) between the treatment groups. </p> <p>For Ewing's sarcoma one trial was identified, evaluating the use of doxorubicin. Descriptive results of overall survival and event‐free survival identified evidence of a significant advantage for patients treated with anthracyclines as compared to patients treated without anthracyclines (P = 0.02 and P = 0.01, respectively). No information on tumour response was provided and, therefore, no conclusions can be made regarding this outcome. </p> <p>For non‐Hodgkin lymphoma one trial was identified, evaluating the use of daunorubicin. It was not possible to evaluate overall survival in this study and, therefore, no conclusions can be made regarding this outcome. Our analysis of event‐free survival showed no evidence of a significant difference between the treatment groups. No information on tumour response was provided and, therefore, no conclusions can be made regarding this outcome. </p> <p>For hepatoblastoma one trial was identified, evaluating the use of doxorubicin. No significant difference in overall survival, event‐free survival and tumour response (defined as complete surgical resection, that is resection of all tumour sites on the basis of surgical findings and on postsurgical imaging) was identified between treatment including and treatment not including anthracyclines. </p> <p>For AML one trial was identified, evaluating the use of daunoxome, that is liposomally entrapped daunorubicin. No significant difference in overall survival and tumour response (defined as complete response after two courses) was identified between treatment including and treatment not including anthracyclines. No information on event‐free survival was provided and, therefore, no conclusions can be made regarding this outcome. In addition to overall survival for all randomised patients, this study reported overall survival in a subgroup of patients with relapsed core binding factor (CBF)‐AML (that is t(8:21) or inv(16)). In patients randomised to treatment without anthracyclines (n = 34) overall survival at seven years was 58%, while in patients randomised to treatment with anthracyclines (n = 36) it was 82%. Since this was a post hoc analysis it was not included in the results of this review. The authors clearly stated that since this was a post hoc analysis this finding needs to be confirmed. </p> <p>Please note that the reason that no significant difference between treatment groups was identified in patients with rhabdomyosarcoma and undifferentiated sarcoma, non‐Hodgkin lymphoma, hepatoblastoma and AML could be due to the fact that the numbers of patients included in these studies were too small to detect a difference between the treatment groups (that is low power). Also, the length of follow‐up could be too short to detect a significant difference between the treatment groups. </p> <p>As mentioned earlier, one of the most serious adverse effects of anthracycline treatment is cardiotoxicity. Therefore, we did not only evaluate the antitumour efficacy of treatment with and without anthracyclines but also the occurrence of cardiotoxicity in both treatment groups. Our meta‐analysis of two trials evaluating cardiac death showed no significant difference between the treatment groups. The same was true for our analysis of one trial evaluating congestive heart failure and our analysis of one trial evaluating acute grade 3 or 4 cardiotoxicity (according to the NCI CTC version 2). One study provided information on asymptomatic cardiac dysfunction but due to the high risk of attrition bias (this outcome was evaluated in only 49% of the patients) results of this study were not included in this systematic review. Please note that the reason that no significant difference between the treatment groups was identified could be due to the fact that the numbers of patients included in these studies were too small to detect a difference between the treatment groups (that is low power). Also, the length of follow‐up could be too short to detect a significant difference between the treatment groups. There is some suggestion of a lower rate of clinical cardiotoxicity in patients who were not treated with anthracyclines. </p> <p>Although there is only a small amount of data on the occurrence of anthracycline‐induced cardiotoxicity available from RCTs, both clinical and asymptomatic anthracycline‐induced cardiac damage has been evaluated in many non‐randomised studies. These studies show that anthracycline‐induced cardiotoxicity is a widely prevalent problem in children. The incidence of clinical heart failure has been reported to be as high as 16% at 0.9 to 4.8 years after treatment (<a href="./references#CD006647-bbs2-0212" title="KremerLCM , vanDalenEC , OffringaM , VoutePA . Frequency and risk factors of anthracycline‐induced clinical heart failure in children: a systematic review. Annals of Oncology2002;13:503‐12. ">Kremer 2002a</a>) and the prevalence of asymptomatic cardiac dysfunction has been reported to be more than 57% at a median of 6.4 years after treatment (<a href="./references#CD006647-bbs2-0213" title="KremerLCM , van derPalHJH , OffringaM , vanDalenEC , VoutePA . Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Annals of Oncology2002;13:819‐29. ">Kremer 2002b</a>). The incidence of anthracycline‐induced cardiotoxicity, both clinical and asymptomatic, seems to increase with a longer follow‐up period (<a href="./references#CD006647-bbs2-0207" title="GreenDM , GrigorievYA , NanB , TakashimaJR , NorkoolPA , D'AngioGJ , et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. Journal of Clinical Oncology2001;19:1926‐34. ">Green 2001</a>; <a href="./references#CD006647-bbs2-0213" title="KremerLCM , van derPalHJH , OffringaM , vanDalenEC , VoutePA . Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Annals of Oncology2002;13:819‐29. ">Kremer 2002b</a>; <a href="./references#CD006647-bbs2-0224" title="VanDalenEC , van derPalHJ , KokWE , CaronHN , KremerLCM . Clinical heart failure in a cohort of children treated with anthracyclines: a long‐term follow‐up study. European Journal of Cancer2006;42:3191‐8. ">Van Dalen 2006</a>). For example, in a cohort study of 830 children with different types of tumour the estimated risk of anthracycline‐induced clinical heart failure increased with time from 2% at two years after the first dose of anthracyclines to 5.5% at 15 years after the first dose of anthracyclines (<a href="./references#CD006647-bbs2-0224" title="VanDalenEC , van derPalHJ , KokWE , CaronHN , KremerLCM . Clinical heart failure in a cohort of children treated with anthracyclines: a long‐term follow‐up study. European Journal of Cancer2006;42:3191‐8. ">Van Dalen 2006</a>). In three of the four studies included in this review that adequately evaluated cardiotoxicity the length of follow‐up was not mentioned, but it is likely that in all studies the follow‐up was relatively short. In the other study the median follow‐up was four years, but only acute cardiotoxicity was assessed. We did not include data on long‐term cardiac follow‐up from the included RCTs in this review because they included only data on some of the randomised patients and as a result the presence of selection bias could not be ruled out in these studies. Furthermore, in most long‐term follow‐up studies data for patients eligible for inclusion in our review could not be separated from results of patients ineligible for our review. However, in the study of <a href="./references#CD006647-bbs2-0148" title="RammelooLA , PostmaA , Sobotka‐PlojharMA , Bink‐BoelkensMT , BergA , VeermanAJ , et al. Low‐dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long‐term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group. Medical and Pediatric Oncology2000;35:13‐9. ">Rammeloo 2000</a>, which was a long‐term cardiac follow‐up study of <a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a>, no late cardiac damage was demonstrated in 90 of the 136 eligible ALL survivors. The minimal follow‐up was 11 years after the last dose of anthracycline therapy. The age at diagnosis ranged from 1.2 to 14.9 years; at the time of the study their age ranged from 14.7 to 31.3 years. It should be noted that in this RCT patients who were randomised to treatment with anthracyclines received a relatively low cumulative anthracycline dose (that is according to the protocol 100 mg/m<sup>2</sup> of daunorubicin) and that the occurrence of anthracycline‐induced cardiotoxicity is dose‐dependent (<a href="./references#CD006647-bbs2-0207" title="GreenDM , GrigorievYA , NanB , TakashimaJR , NorkoolPA , D'AngioGJ , et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. Journal of Clinical Oncology2001;19:1926‐34. ">Green 2001</a>; <a href="./references#CD006647-bbs2-0212" title="KremerLCM , vanDalenEC , OffringaM , VoutePA . Frequency and risk factors of anthracycline‐induced clinical heart failure in children: a systematic review. Annals of Oncology2002;13:503‐12. ">Kremer 2002a</a>; <a href="./references#CD006647-bbs2-0224" title="VanDalenEC , van derPalHJ , KokWE , CaronHN , KremerLCM . Clinical heart failure in a cohort of children treated with anthracyclines: a long‐term follow‐up study. European Journal of Cancer2006;42:3191‐8. ">Van Dalen 2006</a>; <a href="./references#CD006647-bbs2-0225" title="VonHoffDD , LayardMW , BasaP , DavisHLJr , VonHoffAL , RozencweigM , et al. Risk factors for doxorubicin‐induced congestive heart failure. Annals of Internal Medicine1979;91:710‐7. ">Von Hoff 1979</a>). However, it is important not to forget that although the risk of anthracycline‐induced clinical heart failure is significantly increased with a cumulative anthracycline dose of 300 mg/m² or more (<a href="./references#CD006647-bbs2-0224" title="VanDalenEC , van derPalHJ , KokWE , CaronHN , KremerLCM . Clinical heart failure in a cohort of children treated with anthracyclines: a long‐term follow‐up study. European Journal of Cancer2006;42:3191‐8. ">Van Dalen 2006</a>), both clinical and asymptomatic cardiac dysfunction can occur with a lower cumulative anthracycline dose (<a href="./references#CD006647-bbs2-0218" title="LipshultzSE , LipsitzSR , SallanSE , DaltonVM , MoneSM , GelberRD , et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. Journal of Clinical Oncology2005;23:2629‐36. ">Lipshultz 2005</a>; <a href="./references#CD006647-bbs2-0224" title="VanDalenEC , van derPalHJ , KokWE , CaronHN , KremerLCM . Clinical heart failure in a cohort of children treated with anthracyclines: a long‐term follow‐up study. European Journal of Cancer2006;42:3191‐8. ">Van Dalen 2006</a>). The fact that the patients in the study of <a href="./references#CD006647-bbs2-0148" title="RammelooLA , PostmaA , Sobotka‐PlojharMA , Bink‐BoelkensMT , BergA , VeermanAJ , et al. Low‐dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long‐term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group. Medical and Pediatric Oncology2000;35:13‐9. ">Rammeloo 2000</a> did not develop cardiac damage at the time of the study does not exclude the possibility that anthracycline‐induced cardiotoxicity will become visible as they become older. </p> <p>Just as the occurrence of anthracycline‐induced cardiotoxicity is dose‐dependent, it is possible that the cumulative anthracycline dose patients received influenced the antitumour efficacy of treatment. The exact cumulative anthracycline dose was not mentioned in any of the studies, but according to the different protocols the cumulative anthracycline dose ranged from 90 to 420 mg/m<sup>2</sup>. It should be noted that in the AML study and two of the three ALL studies patients received a relatively low cumulative anthracycline dose, that is either 180 mg/m<sup>2</sup> (<a href="./references#CD006647-bbs2-0007" title="KaspersGJ , ZimmermannM , ReinhardtD , GibsonBE , TammingaRY , AleinikovaO , et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology2013;31(5):599‐607. ">Kaspers 2013</a>), 90 mg/m<sup>2</sup> (<a href="./references#CD006647-bbs2-0006" title="EdenOB , LilleymanJS , RichardsS , ShawMP , PetoJ . Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology1991;78:187‐96. ">Eden 1991</a>) or 100 mg/m<sup>2</sup> (<a href="./references#CD006647-bbs2-0015" title="Van derDoes‐van den BergA , vanWeringER , SuciuS , SolbuG , van't VeerMB , RammelooJA , et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology1989;11:125‐33. ">Van der Does 1989</a>). However, despite these low cumulative doses, in all studies there was still a suggestion of better antitumour efficacy with anthracycline therapy. </p> <p>Patient age can be an important prognostic factor for the antitumour efficacy of treatments for different types of tumour (<a href="./references#CD006647-bbs2-0205" title="BiondiA , CiminoG , PietersR , PuiCH . Biological and therapeutic aspects of infant leukemia. Blood2000;96:24‐33. ">Biondi 2000</a>; <a href="./references#CD006647-bbs2-0206" title="GratiasEJ , DomeJS . Current and emerging chemotherapy treatment strategies for Wilms tumor in North America. Paediatric Drugs2008;10:115‐24. ">Gratias 2008</a>; <a href="./references#CD006647-bbs2-0222" title="PietersR , CarrollWL . Biology and treatment of acute lymphoblastic leukemia. Pediatric Clinics of North America2008;55:1‐20. ">Pieters 2008</a>). For example, in ALL infants aged less than one year or children aged 10 years or older have a worse outcome than children aged between one and nine years at diagnosis (<a href="./references#CD006647-bbs2-0205" title="BiondiA , CiminoG , PietersR , PuiCH . Biological and therapeutic aspects of infant leukemia. Blood2000;96:24‐33. ">Biondi 2000</a>; <a href="./references#CD006647-bbs2-0222" title="PietersR , CarrollWL . Biology and treatment of acute lymphoblastic leukemia. Pediatric Clinics of North America2008;55:1‐20. ">Pieters 2008</a>). Patient's age can also be a prognostic factor for the occurrence of cardiotoxicity (<a href="./references#CD006647-bbs2-0212" title="KremerLCM , vanDalenEC , OffringaM , VoutePA . Frequency and risk factors of anthracycline‐induced clinical heart failure in children: a systematic review. Annals of Oncology2002;13:503‐12. ">Kremer 2002a</a>; <a href="./references#CD006647-bbs2-0213" title="KremerLCM , van derPalHJH , OffringaM , vanDalenEC , VoutePA . Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Annals of Oncology2002;13:819‐29. ">Kremer 2002b</a>). Unfortunately, due to a lack of useful data, these factors could not be evaluated in this review and, therefore, no conclusions can be made regarding age as a prognostic factor for these outcomes. </p> <p>The risk of bias in the included studies varied. In most studies bias could not be ruled out due to lack of reporting. However, at the moment this is the best available evidence from RCTs evaluating treatment with and without anthracyclines in children with cancer. With regard to performance bias it should be noted that due to the nature of the interventions, blinding of care providers and patients was virtually impossible. </p> <p>In this review we tried to only perform intention‐to‐treat (ITT) analyses, since they provide the most realistic and unbiased answer to the question of clinical effectiveness (<a href="./references#CD006647-bbs2-0215" title="LachinJM . Statistical considerations in the intent‐to‐treat principle. Controlled Clinical Trials2000;21:167‐89. ">Lachin 2000</a>; <a href="./references#CD006647-bbs2-0216" title="LeeYJ , EllenbergJH , HirtzDG , NelsonKB . Analysis of clinical trials by treatment actually received: is it really an option?. Statistics in Medicine1991;10:1595‐605. ">Lee 1991</a>). However, for the long‐term results of <a href="./references#CD006647-bbs2-0001" title="D'AngioGJ , EvansA , BreslowN , BeckwithB , BishopH , FarewellV , et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer1981;47:2302‐11. ">D'Angio 1981</a> (<a href="./references#CD006647-bbs2-0208" title="GreenDM . The treatment of stages I‐IV favorable histology Wilms' tumor. Journal of Clinical Oncology2004;22:1366‐72. ">Green 2004</a>) and for <a href="./references#CD006647-bbs2-0012" title="PerilongoG , MaibachR , ShaffordE , BrugieresL , BrockP , MorlandB , et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine2009;361:1662‐70. ">Perilongo 2009</a> an ITT analysis was not possible and, therefore, we performed an as‐treated analysis. </p> <p>Eligible RCTs were identified for only seven types of tumour. No appropriate studies were found for other childhood cancers and, therefore, no conclusions can be made regarding the use of anthracyclines in the treatment of these tumours. It should be noted that in this review RCTs including both children and adults were only eligible for inclusion if the majority of participants were children, and the maximal age of the participants did not exceed 30 years. It is possible that there might be evidence on antitumour efficacy and cardiotoxicity of treatment with and without anthracyclines from studies including both children and adults (for examples see the <a href="./references#CD006647-sec-0100" title="">Characteristics of excluded studies</a> table). </p> <p>We are awaiting the results of the currently ongoing studies and studies presented as abstracts during a conference on the use of anthracyclines for the following childhood cancers: hepatoblastoma (N = 1), ALL (N = 2), rhabdomyosarcoma (N = 1) and Wilms' tumour (N = 1). </p> </section> </section> <div class="figures-list"> <div class="figure" id="CD006647-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/urn:x-wiley:14651858:media:CD006647:CD006647-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_t/tCD006647-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006647-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/full#CD006647-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006647-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/urn:x-wiley:14651858:media:CD006647:CD006647-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_t/tCD006647-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.1 Overall survival (Parmar's method was used to obtain the necessary data for the meta‐analyses)." data-id="CD006647-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.1 Overall survival (Parmar's method was used to obtain the necessary data for the meta‐analyses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/full#CD006647-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006647-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/urn:x-wiley:14651858:media:CD006647:CD006647-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_t/tCD006647-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.5 Overall survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the analyses)." data-id="CD006647-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.5 Overall survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the analyses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/full#CD006647-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006647-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/urn:x-wiley:14651858:media:CD006647:CD006647-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_t/tCD006647-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.2 Event‐free survival (Parmar's method was used to obtain the necessary data for the meta‐analyses)." data-id="CD006647-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.2 Event‐free survival (Parmar's method was used to obtain the necessary data for the meta‐analyses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/full#CD006647-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006647-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/urn:x-wiley:14651858:media:CD006647:CD006647-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_t/tCD006647-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.6 Event‐free survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the analyses)." data-id="CD006647-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.6 Event‐free survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the analyses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/full#CD006647-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006647-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/urn:x-wiley:14651858:media:CD006647:CD006647-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_t/tCD006647-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.3 Tumour response." data-id="CD006647-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.3 Tumour response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/full#CD006647-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006647-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/urn:x-wiley:14651858:media:CD006647:CD006647-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_t/tCD006647-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.4 Clinical cardiotoxicity." data-id="CD006647-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.4 Clinical cardiotoxicity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/full#CD006647-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006647-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/urn:x-wiley:14651858:media:CD006647:CD006647-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_t/tCD006647-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 No anthracyclines versus anthracyclines, Outcome 1 Overall survival (Parmar's method was used to obtain the necessary data for the meta‐analysis)." data-id="CD006647-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 No anthracyclines versus anthracyclines, Outcome 1 Overall survival (Parmar's method was used to obtain the necessary data for the meta‐analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/references#CD006647-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006647-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/urn:x-wiley:14651858:media:CD006647:CD006647-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_t/tCD006647-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 No anthracyclines versus anthracyclines, Outcome 2 Event‐free survival (Parmar's method was used to obtain the necessary data for the meta‐analysis)." data-id="CD006647-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 No anthracyclines versus anthracyclines, Outcome 2 Event‐free survival (Parmar's method was used to obtain the necessary data for the meta‐analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/references#CD006647-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006647-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/urn:x-wiley:14651858:media:CD006647:CD006647-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_t/tCD006647-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 No anthracyclines versus anthracyclines, Outcome 3 Tumour response." data-id="CD006647-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 No anthracyclines versus anthracyclines, Outcome 3 Tumour response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/references#CD006647-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006647-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/urn:x-wiley:14651858:media:CD006647:CD006647-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_t/tCD006647-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 No anthracyclines versus anthracyclines, Outcome 4 Clinical cardiotoxicity." data-id="CD006647-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 No anthracyclines versus anthracyclines, Outcome 4 Clinical cardiotoxicity.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/references#CD006647-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006647-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/urn:x-wiley:14651858:media:CD006647:CD006647-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_t/tCD006647-CMP-001-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 No anthracyclines versus anthracyclines, Outcome 5 Overall survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the meta‐analysis)." data-id="CD006647-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 No anthracyclines versus anthracyclines, Outcome 5 Overall survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the meta‐analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/references#CD006647-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006647-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/urn:x-wiley:14651858:media:CD006647:CD006647-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_t/tCD006647-CMP-001-06.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 No anthracyclines versus anthracyclines, Outcome 6 Event‐free survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the meta‐analysis)." data-id="CD006647-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 No anthracyclines versus anthracyclines, Outcome 6 Event‐free survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the meta‐analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/references#CD006647-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/media/CDSR/CD006647/image_n/nCD006647-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="comparison" data-id="CD006647-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">No anthracyclines versus anthracyclines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival (Parmar's method was used to obtain the necessary data for the meta‐analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 ALL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.95, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Wilms' tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.09, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Rhabdomyosarcoma/undifferentiated sarcoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.83, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Hepatoblastoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.41, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 AML</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.94, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Event‐free survival (Parmar's method was used to obtain the necessary data for the meta‐analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 ALL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.76, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Wilms' tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [1.44, 3.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Non‐Hodgkin lymphoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.74, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Hepatoblastoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.42, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Tumour response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 ALL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.99, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Rhabdomyosarcoma / undifferentiated sarcoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.91, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Hepatoblastoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.96, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 AML</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.75, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinical cardiotoxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Cardiac death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.04, 3.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Cardiotoxicity grade 3 or 4 according to NCICTC version 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.2 [0.02, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Overall survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the meta‐analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.77, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Stage II‐III FH and UH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.62, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.65, 3.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Event‐free survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the meta‐analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [1.09, 2.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Stage II‐III FH and UH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.04, 3.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.66, 3.57]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">No anthracyclines versus anthracyclines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006647.pub4/references#CD006647-tbl-0001">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006647.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006647-note-0001">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006647-note-0005">فارسی</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006647\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006647\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006647\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006647\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006647\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006647\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006647\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006647\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006647\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006647\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006647\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006647\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006647\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006647\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006647\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006647\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006647\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006647\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=0TJL4CWK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006647.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006647.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006647.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006647.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006647.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718189246"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006647.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718189250"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006647.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dca407ac3f3fd',t:'MTc0MDcxODE4OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 